



US 20230020192A1

(19) **United States**(12) **Patent Application Publication**
PRAKASH et al.(10) **Pub. No.: US 2023/0020192 A1**(43) **Pub. Date: Jan. 19, 2023**(54) **COMPOUNDS AND METHODS FOR
MODULATING C9ORF72****Publication Classification**(71) Applicants: **IONIS PHARMACEUTICALS, INC.**,
Carlsbad, CA (US); **BOARD OF
REGENTS OF THE UNIVERSITY
OF TEXAS SYSTEM**, Austin, TX
(US)(51) **Int. Cl.**

A61K 31/712 (2006.01)
A61K 31/7125 (2006.01)
C12N 15/113 (2006.01)
C12Q 1/6883 (2006.01)
A61K 31/7115 (2006.01)
A61P 21/00 (2006.01)
A61P 25/28 (2006.01)
A61K 48/00 (2006.01)

(72) Inventors: **Thazha P. PRAKASH**, Carlsbad, CA
(US); **Frank RIGO**, Carlsbad, CA
(US); **David COREY**, Dallas, TX (US)(52) **U.S. Cl.**



CPC *A61K 31/712* (2013.01); *A61K 31/7125*
(2013.01); *C12N 15/113* (2013.01); *C12Q*
1/6883 (2013.01); *A61K 31/7115* (2013.01);
A61P 21/00 (2018.01); *A61P 25/28* (2018.01);
A61K 48/0066 (2013.01); *C12N 2310/14*
(2013.01); *C12N 2310/345* (2013.01); *C12N*
2310/346 (2013.01); *C12N 2310/113*
(2013.01); *C12Q 2600/178* (2013.01)

(21) Appl. No.: **17/665,348**(22) Filed: **Feb. 4, 2022****Related U.S. Application Data**(63) Continuation of application No. 15/772,805, filed on
May 1, 2018, now Pat. No. 11,260,073, filed as
application No. PCT/US16/60106 on Nov. 2, 2016.(60) Provisional application No. 62/249,833, filed on Nov.
2, 2015.

(57)


ABSTRACT

Disclosed herein are compounds and methods for modulat-
ing C9orf72 transcript. Such compounds and methods are
useful to treat, prevent, or ameliorate neurodegenerative
diseases in an individual in need thereof.


Specification includes a Sequence Listing.**C9orf72 sense foci****A.****B.**

FIGS. 1A-D


C9orf72 sense foci




C9orf72 antisense foci




FIGS. 2A-B



FIGS. 3A-B



FIGS. 4A-B



COMPOUNDS AND METHODS FOR MODULATING C9orf72

[0001] This application is a continuation of U.S. application Ser. No. 15/772,805, filed May 1, 2018, as a national phase application under 35 U.S.C. § 371 of International Application No. PCT/US2016/060106, filed Nov. 2, 2016, which claims benefit of priority to U.S. Provisional Application No. 62/249,833, filed Nov. 2, 2015, the entire contents of each of which are hereby incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under Grant Number GM R35118103 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

[0003] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled IONSP0007USC1_ST25.txt, created Feb. 4, 2022, which is 51 kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD

[0004] Provided are compounds and methods for inhibiting expression, activity, or foci formation of C9orf72 in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticobasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerebellar degeneration (OPCD).

BACKGROUND

[0005] Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized clinically by progressive paralysis leading to death from respiratory failure, typically within two to three years of symptom onset (Rowland and Shneider, *N. Engl. J. Med.*, 2001, 344, 1688-1700). ALS is the third most common neurodegenerative disease in the Western world (Hirtz et al., *Neurology*, 2007, 68, 326-337), and there are currently no effective therapies. Approximately 10% of cases are familial in nature, whereas the bulk of patients diagnosed with the disease are classified as sporadic as they appear to occur randomly throughout the population (Chio et al., *Neurology*, 2008, 70, 533-537). There is growing recognition, based on clinical, genetic, and epidemiological data, that ALS and frontotemporal dementia (FTD) represent an overlapping continuum of disease, characterized pathologically by the presence of TDP-43 positive inclusions throughout the central nervous system (Lillo and Hodges, *J. Clin. Neurosci.*, 2009, 16, 1131-1135; Neumann et al., *Science*, 2006, 314, 130-133).

[0006] To date, a number of genes have been discovered as causative for classical familial ALS, for example, SOD1, TARDBP, FUS, OPTN, and VCP (Johnson et al., *Neuron*, 2010, 68, 857-864; Kwiatkowski et al., *Science*, 2009, 323, 1205-1208; Maruyama et al., *Nature*, 2010, 465, 223-226; Rosen et al., *Nature*, 1993, 362, 59-62; Sreedharan et al., *Science*, 2008, 319, 1668-1672; Vance et al., *Brain*, 2009,

129, 868-876). Recently, linkage analysis of kindreds involving multiple cases of ALS, FTD, and ALS-FTD had suggested that there was an important locus for the disease on the short arm of chromosome 9 (Boxer et al., *J. Neurol. Neurosurg. Psychiatry*, 2011, 82, 196-203; Morita et al., *Neurology*, 2006, 66, 839-844; Pearson et al. *J. Neurol.*, 2011, 258, 647-655; Vance et al., *Brain*, 2006, 129, 868-876). This mutation has been found to be the most common genetic cause of ALS and FTD. It is postulated that the ALS-FTD causing mutation is a large hexanucleotide (GGGGCC) repeat expansion in the first intron of the C9orf72 gene (Renton et al., *Neuron*, 2011, 72, 257-268; DeJesus-Hernandez et al., *Neuron*, 2011, 72, 245-256). A founder haplotype, covering the C9orf72 gene, is present in the majority of cases linked to this region (Renton et al., *Neuron*, 2011, 72, 257-268). This locus on chromosome 9p21 accounts for nearly half of familial ALS and nearly one-quarter of all ALS cases in a cohort of 405 Finnish patients (Laaksovirta et al., *Lancet Neurol.*, 2010, 9, 978-985). There are currently no effective therapies to treat such neurodegenerative diseases.

[0007] Targeting disease-causing gene sequences was first suggested more than thirty years ago (Belikova et al., *Tet. Lett.*, 1967, 37, 3557-3562), and antisense activity was demonstrated in cell culture more than a decade later (Zamecnik et al., *Proc. Natl. Acad. Sci. U.S.A.*, 1978, 75, 280-284). One advantage of antisense technology in the treatment of a disease or condition that stems from a disease-causing gene is that it is a direct genetic approach that has the ability to modulate (increase or decrease) the expression of specific disease-causing genes. Another advantage is that validation of a therapeutic target using antisense compounds results in direct and immediate discovery of the drug candidate; the antisense compound is the potential therapeutic agent.

[0008] Generally, the principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates gene expression, activity, or function. The modulation of gene expression can be achieved by, for example, target degradation or occupancy-based inhibition. Antisense technology is an effective means for modulating the expression of one or more specific gene products and can therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications. Chemically modified nucleosides are routinely used for incorporation into antisense compounds to enhance one or more properties, such as nuclease resistance, pharmacokinetics or affinity for a target RNA. In 1998, the antisense compound, Vitravene® (fomivirsen; developed by Isis Pharmaceuticals Inc., Carlsbad, Calif.) was the first antisense drug to achieve marketing clearance from the U.S. Food and Drug Administration (FDA), and is currently a treatment of cytomegalovirus (CMV)-induced retinitis in AIDS patients.

BRIEF SUMMARY

[0009] Provided herein are compounds comprising modified oligonucleotides complementary to a C9orf72 transcript. Such oligomeric compounds comprise a 5'-terminal group, wherein the 5'-terminal group is a phosphorus moiety. In certain embodiments, the modified oligonucleotides provided herein are expected to have enhanced nuclease stability. In certain embodiments, the modified oligonucleotides are expected to hybridize to a portion of a target RNA resulting in modulation of normal function of the target

RNA, wherein the target RNA is a C9orf72 transcript. In certain embodiments, the modified oligonucleotides are complementary to the hexanucleotide repeat region of a C9orf72 transcript. In certain embodiments, the modified oligonucleotides are complementary to the hexanucleotide repeat region of a C9orf72 sense transcript. In certain embodiments, the modified oligonucleotides are complementary to the hexanucleotide repeat region of a C9orf72 antisense transcript.

[0010] The compounds are defined individually in further detail herein. It is to be understood that the oligomeric compounds provided herein include all combinations of the embodiments disclosed and variables defined herein.

[0011] The following non-limiting numbered embodiments are provided.

[0012] Embodiment 1. A compound comprising a modified oligonucleotide and a terminal group at the 5'-end of the modified oligonucleotide, wherein

[0013] the modified oligonucleotide consists of 13 to 30 linked nucleosides and has a nucleobase sequence comprising a complementary region having at least 7 contiguous nucleobases complementary to an equal-length portion within a target region of a target nucleic acid, wherein the target nucleic acid is a C9orf72 transcript;

[0014] and wherein the terminal group comprises a phosphorus moiety.

[0015] Embodiment 2. The compound of embodiment 1, wherein the target region of the C9orf72 transcript comprises a hexanucleotide repeat.

[0016] Embodiment 3. The compound of any of embodiments 1 or 2, wherein the target region of the C9orf72 transcript is within a hexanucleotide repeat region.

[0017] Embodiment 4. The compound of any of embodiments 1 to 3, wherein the complementary region comprises at least 10 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

[0018] Embodiment 5. The compound of any of embodiments 1 to 3, wherein the complementary region comprises at least 12 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

[0019] Embodiment 6. The compound of any of embodiments 1 to 3, wherein the complementary region comprises at least 14 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.


[0020] Embodiment 7. The compound of any of embodiments 1 to 3, wherein the complementary region comprises at least 16 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

[0021] Embodiment 8. The compound of any of embodiments 1 to 3, wherein the complementary region comprises at least 18 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

[0022] Embodiment 9. The compound of any of embodiments 1 to 8, wherein the C9orf72 transcript is a C9orf72 sense transcript.

[0023] Embodiment 10. The compound of any of embodiments 1 to 8, wherein the C9orf72 transcript is a C9orf72 antisense transcript.

[0024] Embodiment 11. The compound of any of embodiments 1 to 10, wherein the 5'-terminal nucleoside and terminal group of the compound has Formula I:




I

[0025] wherein:

[0026] T₁ is a phosphorus moiety;

[0027] A has a formula selected from among:



[0028] Q₁ and Q₂ are each independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, and N(R₃)(R₄);

[0029] Q₃ is selected from among: O, S, N(R₅), and C(R₆)(R₇);

[0030] each R₃, R₄, R₅, R₆ and R₇ is independently selected from among: H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, and C₁-C₆ alkoxy;

[0031] M₃ is selected from among: O, S, NR₁₄, C(R₁₅)(R₁₆), C(R₁₅)(R₁₆)C(R₁₇)(R₁₈), C(R₁₅)=C(R₁₇), OC(R₁₅)(R₁₆), and OC(R₁₅)(Bx₂);

[0032] R₁₄ is selected from among: H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;


[0033] R₁₅, R₁₆, R₁₇ and R₁₈ are each independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

[0034] if Bx₂ is present, then Bx₂ is a nucleobase and Bx₁ is selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

[0035] if Bx₂ is not present, then Bx₁ is a nucleobase;

- [0036]** either each of J_4 , J_5 , J_6 and J_7 is independently selected from among: H, halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, and substituted C_2 - C_6 alkynyl;
- [0037]** or J_4 forms a bridge with one of J_5 or J_7 wherein the bridge comprises from 1 to 3 linked biradical groups selected from O, S, NR_{19} , $C(R_{20})(R_{21})$, $C(R_{20})=C(R_{21})$, $C[=C(R_{20})(R_{21})]$ and $C(=O)$ and the other two of J_5 , J_6 and J_7 are independently selected from among: H, halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, and substituted C_2 - C_6 alkynyl;
- [0038]** each R_{19} , R_{20} and R_{21} is independently selected from among: H, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl or substituted C_2 - C_6 alkynyl;
- [0039]** one of G_1 and G_2 is selected from among: H, OH, halogen and $O-[C(R_8)(R_9)]_n-[(C=O)_m-X_1]_j-Z$;
- and the other of G_1 and G_2 is: $O-T_2$;
- [0040]** T_2 is an internucleoside linking group linking the 5'-terminal nucleoside of Formula I to the remainder of the oligonucleotide;
- [0041]** each R_8 and R_9 is independently selected from among: H, halogen, C_1 - C_6 alkyl, and substituted C_1 - C_6 alkyl;
- [0042]** X_1 is O, S or $N(E_1)$;
- [0043]** Z is selected from among: H, halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, substituted C_2 - C_6 alkynyl, and $N(E_2)(E_3)$;
- [0044]** E_1 , E_2 and E_3 are each independently selected from among: H, C_1 - C_6 alkyl, and substituted C_1 - C_6 alkyl;
- [0045]** n is from 1 to 6;
- [0046]** m is 0 or 1;
- [0047]** j is 0 or 1;
- [0048]** provided that, if j is 1, then Z is other than halogen or $N(E_2)(E_3)$;
- [0049]** each substituted group comprises one or more optionally protected substituent groups independently selected from among: a halogen, OJ_1 , $N(J_1)(J_2)$, $=NJ_1$, SJ_1 , N_3 , CN , $OC(=X_2)J_1$, $OC(=X_2)N(J_1)(J_2)$, and $C(=X_2)N(J_1)(J_2)$;
- [0050]** X_2 is O, S or NJ_3 ; and
- [0051]** each J_1 , J_2 and J_3 is independently selected from among: H and C_1 - C_6 alkyl.
- [0052]** Embodiment 12. The compound of embodiment 11, wherein M_3 is selected from among: O, $CH=CH$, OCH_2 , and $OC(H)(Bx_2)$.
- [0053]** Embodiment 13. The compound of embodiment 11, wherein M_3 is O.
- [0054]** Embodiment 14. The compound of any of embodiments 11 to 13, wherein each of J_4 , J_5 , J_6 and J_7 is H.
- [0055]** Embodiment 15. The compound of any of embodiments 11 to 14, wherein J_4 forms a bridge with either J_5 or J_7 .

- [0056]** Embodiment 16. The compound of any of embodiments 11 to 15, wherein A has the formula:



- [0057]** wherein:


- [0058]** Q_1 and Q_2 are each independently selected from among: H, halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, and substituted C_1 - C_6 alkoxy.

- [0059]** Embodiment 17. The compound of embodiment 16, wherein each of Q_1 and Q_2 is H.

- [0060]** Embodiment 18. The compound of embodiment 16, wherein Q_1 and Q_2 are each independently selected from among: H and a halogen.

- [0061]** Embodiment 19. The compound of embodiment 16, wherein one of Q_1 and Q_2 is H and the other of Q_1 and Q_2 is F, CH_3 or OCH_3 .

- [0062]** Embodiment 20. The compound of any of embodiments 11 to 19, wherein T_1 has the formula:



- [0063]** wherein:

- [0064]** R_a and R_c are each independently selected from among: hydroxyl, protected hydroxyl, thiol, protected thiol, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, amino, protected amino or substituted amino; and

- [0065]** R_b is O or S.

- [0066]** Embodiment 21. The compound of embodiment 20, wherein R_b is O and R_a and R_c are each, independently selected from among: OH, OCH_3 , OCH_2CH_3 , $OCH(CH_3)_2$.


- [0067]** Embodiment 22. The compound of any of embodiments 11 to 21, wherein one of G_1 and G_2 is selected from among: a halogen, OCH_3 , OCH_2F , $OCHF_2$, OCF_3 , OCH_2CH_3 , $O(CH_2)_2F$, OCH_2CHF_2 , OCH_2CF_3 , $OCH_2-CH=CH_2$, $O(CH_2)_2-OCH_3$, $O(CH_2)_2-SCH_3$, $O(CH_2)_2-OCF_3$, $O(CH_2)_3-N(R_{10})(R_{11})$, $O(CH_2)_2-ON(R_{10})(R_{11})$, $O(CH_2)_2-O(CH_2)_2-N(R_{10})(R_{11})$, $OCH_2C(=O)-N(R_{10})(R_{11})$, $OCH_2C(=O)-N(R_{12})-(CH_2)_2-N(R_{10})(R_{11})$, and $O(CH_2)_2-N(R_{12})-C(=NR_{13})[N(R_{10})(R_{11})]$; wherein R_{10} , R_{11} , R_{12} and R_{13} are each, independently, H or C_1 - C_6 alkyl.

- [0068]** Embodiment 23. The compound of any of embodiments 11 to 22, wherein one of G_1 and G_2 is selected from among: a halogen, OCH_3 , OCF_3 , OCH_2CH_3 , OCH_2CF_3 , $OCH_2-CH=CH_2$, $O(CH_2)_2-OCH_3$, $O(CH_2)_2-O(CH_2)_2-N(CH_3)_2$, $OCH_2C(=O)-N(H)CH_3$, $OCH_2C(=O)-N(H)-(CH_2)_2-N(CH_3)_2$, and $OCH_2-N(H)-C(=NH)NH_2$.


[0069] Embodiment 24. The compound of any of embodiments 11 to 23, wherein one of G_1 and G_2 is selected from among: F, OCH_3 , and $O(CH_2)_2-OCH_3$.

[0070] Embodiment 25. The compound of embodiment 24, wherein one of G_1 and G_2 is $O(CH_2)_2-OCH_3$.

[0071] Embodiment 26. The compound of any of embodiments 11 to 25, wherein the 5'-terminal nucleoside and terminal group of the compound has Formula III:




[0072] Embodiment 27. The compound of embodiment 26, wherein A has the formula:



[0073] wherein Q_1 and Q_2 are each independently selected from among: H, a halogen, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_1-C_6 alkoxy, and substituted C_1-C_6 alkoxy.

[0074] Embodiment 28. The compound of embodiment 27, wherein Q_1 and Q_2 are each independently selected from among: H, F, CH_3 , and OCH_3 .

[0075] Embodiment 29. The compound of any of embodiments 11 to 28, wherein the 5'-terminal nucleoside and the terminal group has Formula V:



[0076] wherein:

[0077] Bx is selected from among: uracil, thymine, cytosine, 5-methyl cytosine, adenine, and guanine;

[0078] one of G_1 and G_2 is selected from among: a halogen, OCH_3 , OCF_3 , OCH_2CH_3 , OCH_2CF_3 , $OCH_2-CH=CH_2$, $O(CH_2)_2-OCH_3$, $O(CH_2)_2-O(CH_2)_2-N(CH_3)_2$, $OCH_2C(=O)-N(H)CH_3$, $OCH_2C(=O)-N(H)-(CH_2)_2-N(CH_3)_2$ and $OCH_2-N(H)-C(=NH)NH_2$;


[0079] and the other of G_1 and G_2 is $O-T_2$, wherein T_2 is a phosphorothioate internucleoside linking group linking the compound of Formula V to the remainder of the oligonucleotide.

[0080] Embodiment 30. The compound of any of embodiments 1 to 29, wherein the modified oligonucleotide comprises at least two modified sugar moieties.

[0081] Embodiment 31. The compound of embodiment 30, wherein the modified oligonucleotide is fully modified.

[0082] Embodiment 32. The compound of any of embodiments 30 to 31, wherein each modified sugar moiety is independently selected from among: 2'-F, 2'-MOE, 2'-OMe, LNA, F-HNA, and cEt.

[0083] Embodiment 33. The compound of any of embodiments 1 to 32, wherein the modified oligonucleotide comprises at least one region having sugar motif:



[0084] wherein

[0085] A is a modified nucleoside of a first type,

[0086] B is a modified nucleoside of a second type;

[0087] each x and each y is independently 1 or 2;

[0088] z is 0 or 1;

[0089] q is 3-15.

[0090] Embodiment 34. The compound of embodiment 33, wherein each x and each y is 1.

[0091] Embodiment 35. The compound of embodiment 33 or 34, wherein A is a modified nucleoside selected from among: a 2'-F, a 2'-OMe, and a F-HNA modified nucleoside.

[0092] Embodiment 36. The compound of embodiment 33 or 34, wherein B is a modified nucleoside selected from among: a 2'-F, a 2'-OMe, and a F-HNA modified nucleoside.

[0093] Embodiment 37. The compound of any of embodiments 33 to 36, wherein A is a 2'-F modified nucleoside and B is a 2'-OMe modified nucleoside.

[0094] Embodiment 38. The compound of any of embodiments 33 to 36, wherein B is a 2'-F modified nucleoside and A is a 2'-OMe modified nucleoside.

[0095] Embodiment 39. The compound of any of embodiments 1 to 38, wherein the modified oligonucleotide comprises 1-4 3'-terminal nucleosides, each comprising the same modified sugar moiety, wherein the modified sugar moiety of the 1-4 3'-terminal nucleosides is different from the modified sugar moiety of the immediately adjacent nucleoside.

[0096] Embodiment 40. The compound of embodiment 39, wherein the 3'-terminal nucleosides are each 2'-MOE nucleosides.

[0097] Embodiment 41. The compound of embodiment 39 or 40 comprising two 3'-terminal nucleosides.

[0098] Embodiment 42. The compound of any of embodiments 1 to 41, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

[0099] Embodiment 43. The compound of any of embodiments 1 to 42, wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphorothioate internucleoside linkage and an unmodified, phosphate internucleoside linkage.

[0100] Embodiment 44. The compound of embodiment 42 or 43, wherein each of the 6-10 3'-most internucleoside linkages of the modified oligonucleotide is a phosphorothioate internucleoside linkage.

[0101] Embodiment 45. The compound of any of embodiments 42 to 44, wherein the 5'-most inter-

- nucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage.
- [0102] Embodiment 46. The compound of any of embodiments 42 to 45, wherein the modified oligonucleotide comprises a region of at least 4 internucleoside linkages that alternate between phosphorothioate and phosphate internucleoside linkages.
- [0103] Embodiment 47. The compound of any of embodiments 1 to 46, comprising the motif:
- [0104] 5'-(Nucleoside of Formula I, III, or V)-s-(A-s-B-o-A)_x(-s-B)_Y
- [0105] wherein:
- [0106] A is a nucleoside of a first type;
- [0107] B is a nucleoside of a second type;
- [0108] s is a phosphorothioate internucleoside linkage;
- [0109] is a phosphate internucleoside linkage;
- [0110] x is 1-8; and
- [0111] Y is 1 or 0.
- [0112] Embodiment 48. The compound of any of embodiments 1 to 47, comprising the motif:
- $$(A-s-B-s-A)_2(-s-B)_q-s-(D)-(-s-D)_r-3'$$
- [0113] wherein:
- [0114] s is a phosphorothioate linkage;
- [0115] A is a nucleoside of a first type;
- [0116] B is a nucleoside of a second type;
- [0117] D is a nucleoside of a third type;
- [0118] Z is 1-5;
- [0119] q is 1 or 0; and
- [0120] and r is 0-3.
- [0121] Embodiment 49. The compound of embodiment 47 or 48, wherein A is a 2'-F modified nucleoside.
- [0122] Embodiment 50. The compound of any of embodiments 47 to 49, wherein B is a 2'-OMe modified nucleoside.
- [0123] Embodiment 51. The compound of any of embodiments 48 to 50, wherein D is a 2'-MOE modified nucleoside.
- [0124] Embodiment 52. The compound of any of embodiments 1 to 46, comprising the motif:
- [0125] (Nucleoside of Formula V)-s-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-s-A-s-B-s-A-s-B-s-D-s-D-s
- [0126] wherein:
- [0127] s is a phosphorothioate internucleoside linkage;
- [0128] is a phosphate internucleoside linkage;
- [0129] A is a nucleoside of a first type;
- [0130] B is a nucleoside of a second type; and
- [0131] D is a nucleoside of a third type.
- [0132] Embodiment 53. The compound of any of embodiments 1 to 46, consisting of the motif:
- [0133] (Nucleoside of Formula V)-s-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-o-A-s-B-s-A-s-B-s-A-s-B-s-D-s-D-s
- [0134] wherein:
- [0135] s is a phosphorothioate linkage;
- [0136] is a phosphate internucleoside linkage;
- [0137] A is a nucleoside of a first type;
- [0138] B is a nucleoside of a second type; and
- [0139] D is a nucleoside of a third type.
- [0140] Embodiment 54. The compound of any of embodiments 52 to 53, wherein A is a 2'-F modified nucleoside.
- [0141] Embodiment 55. The compound of any of embodiments 52 to 53, wherein B is a 2'-OMe modified nucleoside.
- [0142] Embodiment 56. The compound of any of embodiments 52 to 55, wherein D is a 2'-MOE modified nucleoside.
- [0143] Embodiment 57. The compound of any of embodiments 1 to 56, wherein the modified oligonucleotide has two mismatches relative to the target region of the C9orf72 transcript.
- [0144] Embodiment 58. The compound of any of embodiments 1 to 56, wherein the modified oligonucleotide has three mismatches relative to the target region of the C9orf72 transcript.
- [0145] Embodiment 59. The compound of any of embodiments 1 to 56, wherein the modified oligonucleotide has four mismatches relative to the target region of the C9orf72 transcript.
- [0146] Embodiment 60. The compound of any of embodiments 1 to 56, wherein the modified oligonucleotide has five mismatches relative to the target region of the C9orf72 transcript.
- [0147] Embodiment 61. The compound of any of embodiments 1 to 56, wherein the modified oligonucleotide has six mismatches relative to the target region of the C9orf72 transcript.
- [0148] Embodiment 62. The compound of any of embodiments 57 to 61, wherein the 5'-most nucleobase and 3'-most nucleobase of the modified oligonucleotide are mismatches relative to the target region of the C9orf72 transcript.
- [0149] Embodiment 63. The compound of any of embodiments 58 to 61, wherein the 5'-most nucleobase and the two 3'-most nucleobases of the modified oligonucleotide are mismatches relative to the target region of the C9orf72 transcript.
- [0150] Embodiment 64. The compound of any of embodiments 57 to 61, wherein the nucleobases at positions 9 and 14 of the modified oligonucleotide are mismatches relative to the target region of the C9orf72 transcript.
- [0151] Embodiment 65. The compound of any of embodiments 58 to 61, wherein the nucleobases at positions 9, 10, and 11 of the modified oligonucleotide are mismatches relative to the target region of the C9orf72 transcript.
- [0152] Embodiment 66. The compound of any of embodiments 1 to 65, wherein the complementary region is between the 5'-most nucleoside and the two 3'-most nucleosides of the modified oligonucleotide and is 100% complementary to the target region of the C9orf72 transcript.
- [0153] Embodiment 67. The compound of any of embodiments 1 to 65, wherein the complementary region is between the 5'-most nucleoside and the two 3'-most nucleosides of the modified oligonucleotide and is 90% complementary to the target region of the C9orf72 transcript.
- [0154] Embodiment 68. The compound of any of embodiments 1 to 65, wherein the complementary region is between the 5'-most nucleoside and the two

3'-most nucleosides of the modified oligonucleotide and is 80% complementary to the target region of the C9orf72 transcript.

[0155] Embodiment 69. The compound of any of embodiments 1 to 68, wherein each of the nucleobases in the complementary region of the modified oligonucleotide is selected from among: adenine, guanine, cytosine, 5'-methylcytosine, thymine, and uracil.

[0156] Embodiment 70. The compound of any of embodiments 1 to 69, wherein each of the nucleobases in the modified oligonucleotide is selected from among: adenine, guanine, cytosine, 5'-methylcytosine, thymine, and uracil.

[0157] Embodiment 71. The compound of any of embodiments 1 to 70, wherein the modified oligonucleotide does not comprise a modified nucleobase.


[0158] Embodiment 72. The compound of any of embodiments 1 to 70, wherein the modified oligonucleotide comprises 5-methylcytosine.

[0159] Embodiment 73. The compound of any of embodiments 1 to 8 or 10 to 72, wherein the nucleobase sequence of the oligonucleotide comprises a nucleobase sequence selected from among: SEQ ID NO: 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 49.

[0160] Embodiment 74. The compound of any of embodiments 1 to 9 or 11 to 72, wherein the nucleobase sequence of the oligonucleotide comprises a nucleobase sequence selected from among: SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, and 25.

[0161] Embodiment 75. The compound of any of embodiments 1 to 74, wherein the phosphorus moiety is an unmodified phosphate.

[0162] Embodiment 76. The compound of any of embodiments 1 to 74, wherein the phosphorus moiety is a 5'-(E)-vinylphosphonate group having the formula:



[0163] Embodiment 77. The compound of any of embodiments 1 to 76, wherein the compound comprises an unlocked nucleic acid or an abasic nucleoside.

[0164] Embodiment 78. The compound of embodiment 77, wherein the compound comprises an unlocked nucleic acid.

[0165] Embodiment 79. The compound of embodiment 78, wherein the nucleobase attached to the sugar moiety of the unlocked nucleic acid is mismatched relative to the corresponding nucleobase of the target region of the C9orf72 transcript.

[0166] Embodiment 80. The compound of any of embodiments 1 to 79, wherein the compound is an oligomeric compound.

[0167] Embodiment 81. The compound of embodiment 80, wherein the compound consists of the oligomeric compound.

[0168] Embodiment 82. The compound of any of embodiments 80 or 81, wherein the oligomeric compound is paired with a second oligomeric compound to form a duplex.

[0169] Embodiment 83. The compound of any of embodiments 1 to 81, wherein the compound is single-stranded.

[0170] Embodiment 84. A pharmaceutical composition comprising the compound of any of embodiments 1 to 83, and a pharmaceutically acceptable carrier or diluent.

[0171] Embodiment 85. A method of treating a neurodegenerative disease comprising contacting a cell with the compound or composition of any of embodiments 1 to 84.

[0172] Embodiment 86. A method of reducing C9orf72 foci comprising contacting a cell with the compound or composition of any of embodiments 1 to 84.

[0173] Embodiment 87. The method of embodiments 85 or 86, wherein the cell is in vitro.

[0174] Embodiment 88. The method of embodiments 85 or 86, wherein the cell is in an animal.

[0175] Embodiment 89. The method of embodiment 88, wherein the animal is a human.

[0176] Embodiment 90. Use of the compound or composition of any of embodiments 1 to 84 for the manufacture of a medicament for treating a neurodegenerative disease.

[0177] Embodiment 91. Use of the compound or composition of any of embodiments 1 to 84 for treating a neurodegenerative disease.

[0178] Embodiment 92. The method or use of any of embodiments 85 or 89 to 91, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.

BRIEF DESCRIPTION OF FIGURES

[0179] FIGS. 1A-D show the percentage of observed cells containing C9orf72 sense or antisense foci and the number of foci per 100 cells for cells treated with a negative control oligonucleotide ("CM"), positive control siRNA, or Isis No. 742048, 742054, 742072, or 742078.

[0180] FIGS. 2A-B show the percentage of observed cells containing C9orf72 sense foci and the number of foci per 100 cells for cells treated with a control compound or modified oligonucleotide.

[0181] FIGS. 3A-B show the percentage of observed cells containing C9orf72 antisense foci and the number of foci per 100 cells for cells treated with a control compound or modified oligonucleotide.

[0182] FIGS. 4A-B show the percentage of observed cells containing C9orf72 sense foci and the number of foci per 100 cells for cells treated with a control compound or modified oligonucleotide lacking a 5'-phosphate.

DETAILED DESCRIPTION

[0183] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. Herein, the use of the singular includes the plural unless specifically stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and com-

ponents comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

[0184] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

Definitions

[0185] Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art.

[0186] Unless otherwise indicated, the following terms have the following meanings:

[0187] “2'-deoxynucleoside” means a nucleoside comprising 2'-H(H) furanosyl sugar moiety, as found in naturally occurring deoxyribonucleic acids (DNA). In certain embodiments, a 2'-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (uracil).

[0188] “2'-substituted nucleoside” or “2'-modified nucleoside” means a nucleoside comprising a 2'-substituted or 2'-modified sugar moiety. As used herein, “2'-substituted” or “2'-modified” in reference to a sugar moiety means a sugar moiety comprising at least one 2-substituent group other than H or OH.

[0189] “Antisense activity” means any detectable and/or measurable change attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound. In certain embodiments, antisense activity is a change in splicing of a pre-mRNA nucleic acid target. In certain embodiments, antisense activity is a change in the localization or structural formation of a nucleic acid target. In certain such embodiments, antisense activity is a decrease in foci formation of a nucleic acid target.

[0190] “Antisense compound” means a compound comprising an antisense oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group.

[0191] “Antisense oligonucleotide” means an oligonucleotide that (1) has a nucleobase sequence that is at least partially complementary to a target nucleic acid and that (2) is capable of producing an antisense activity in a cell or animal.

[0192] “Ameliorate” in reference to a treatment means improvement in at least one symptom relative to the same symptom in the absence of the treatment. In certain embodiments, amelioration is the reduction in the severity or frequency of a symptom or the delayed onset or slowing of progression in the severity or frequency of a symptom.

[0193] “Bicyclic nucleoside” or “BNA” means a nucleoside comprising a bicyclic sugar moiety. As used herein, “bicyclic sugar” or “bicyclic sugar moiety” means a modified sugar moiety comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring thereby forming a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the bicyclic sugar moiety does not comprise a furanosyl moiety.

[0194] “C9orf72 antisense transcript” means a RNA produced from the non-coding strand (also antisense strand and template strand) of the C9orf72 gene. The C9orf72 antisense transcript differs from the canonically transcribed “C9orf72 sense transcript”, which is a RNA produced from the coding strand (also sense strand) of the C9orf72 gene.

[0195] “C9orf72 associated disease” means any disease associated with any C9orf72 nucleic acid or expression product thereof, regardless of which DNA strand the C9orf72 nucleic acid or expression product thereof is derived from. Such diseases may include a neurodegenerative disease. Such neurodegenerative diseases may include ALS and FTD.

[0196] “C9orf72 foci” means nuclear foci comprising a C9orf72 transcript. In certain embodiments, C9orf72 foci comprises at least one C9orf72 sense transcript (herein “C9orf72 sense foci”). In certain embodiments, C9orf72 sense foci comprise C9orf72 sense transcripts comprising any of the following hexanucleotide repeats: GGGGCC, GGGGGG, GGGGGC, and/or GGGGCG. In certain embodiments, a C9orf72 foci comprises at least one C9orf72 antisense transcript (herein “C9orf72 antisense foci”). In certain embodiments, C9orf72 antisense foci comprise C9orf72 antisense transcripts comprising any of the following hexanucleotide repeats: GGCCCC, CCCCCC, GCCCCC, and/or CGCCCC. In certain embodiments, C9orf72 foci comprise both C9orf72 sense transcripts and C9orf72 antisense transcripts.

[0197] “C9orf72 hexanucleotide repeat” means a portion of a C9orf72 transcript that is 6 nucleotides in length and appears consecutively in the transcript at least two times. In certain embodiments, the C9orf72 hexanucleotide repeat sequence is GGCCCC or CCGGGG. A “C9orf72 hexanucleotide repeat region” is a region of a C9orf72 transcript containing only consecutive hexanucleotide repeats.

[0198] “C9orf72 hexanucleotide repeat expansion associated disease” means any disease associated with a C9orf72 nucleic acid containing a hexanucleotide repeat expansion. In certain embodiments, the hexanucleotide repeat expansion may comprise any of the following hexanucleotide repeats: GGGGCC, GGGGGG, GGGGGC, GGGGCG, GGCCCC, CCCCCC, GCCCCC, and/or CGCCCC. In certain embodiments, the hexanucleotide repeat is repeated at least 24 times. Such diseases may include a neurodegenerative disease. Such neurodegenerative diseases may include ALS and FTD.

[0199] “C9orf72 nucleic acid” means any nucleic acid derived from the C9orf72 locus, regardless of which DNA strand the C9orf72 nucleic acid is derived from. In certain embodiments, a C9orf72 nucleic acid includes a DNA sequence encoding C9orf72, an RNA sequence transcribed from DNA encoding C9orf72 including genomic DNA comprising introns and exons (i.e., pre-mRNA), and an mRNA sequence encoding C9orf72. “C9orf72 mRNA” means an mRNA encoding a C9orf72 protein. In certain embodiments, a C9orf72 nucleic acid includes transcripts produced from the coding strand of the C9orf72 gene. C9orf72 sense transcripts are examples of C9orf72 nucleic acids. In certain embodiments, a C9orf72 nucleic acid includes transcripts produced from the non-coding strand of the C9orf72 gene. C9orf72 antisense transcripts are examples of C9orf72 nucleic acids.

[0200] “C9orf72 pathogenic associated mRNA variant” means the C9orf72 mRNA variant processed from a C9orf72

pre-mRNA variant containing the hexanucleotide repeat. A C9orf72 pre-mRNA contains the hexanucleotide repeat when transcription of the pre-mRNA begins in the region from the start site of exon 1A to the start site of exon 1B, e.g., nucleotides 1107 to 1520 of the genomic sequence (SEQ ID NO: 1, the complement of GENBANK Accession No. NT_008413.18 truncated from nucleosides 27535000 to 27565000). In certain embodiments, the level of a C9orf72 pathogenic associated mRNA variant is measured to determine the level of a C9orf72 pre-mRNA containing the hexanucleotide repeat in a sample.

[0201] “C9orf72 transcript” means a RNA transcribed from C9orf72. In certain embodiments, a C9orf72 transcript is a C9orf72 sense transcript. In certain embodiments, a C9orf72 transcript is a C9orf72 antisense transcript. In certain embodiments, a C9orf72 transcript comprises nucleotides upstream of nucleotide 1520 of SEQ ID NO: 1.

[0202] “Complementary” in reference to an oligonucleotide means that at least 70% of the nucleobases of such oligonucleotide or one or more regions thereof and the nucleobases of another nucleic acid or one or more regions thereof are capable of hydrogen bonding with one another when the nucleobase sequence of the oligonucleotide and the other nucleic acid are aligned in opposing directions. Complementary nucleobases means nucleobases that are capable of forming hydrogen bonds with one another.

[0203] Complementary nucleobase pairs include, but unless otherwise specific are not limited to, adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), 5-methyl cytosine (mC) and guanine (G). Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. As used herein, “fully complementary” or “100% complementary” in reference to oligonucleotides means that such oligonucleotides are complementary to another oligonucleotide or nucleic acid at each nucleoside of the oligonucleotide.

[0204] “Conjugate group” means a group of atoms that is directly or indirectly attached to an oligonucleotide. Conjugate groups include a conjugate moiety and a conjugate linker that attaches the conjugate moiety to the oligonucleotide.

[0205] “Conjugate linker” means a group of atoms comprising at least one bond that connects a conjugate moiety to an oligonucleotide.

[0206] “Conjugate moiety” means a group of atoms that is attached to an oligonucleotide via a conjugate linker.

[0207] “Contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediately adjacent to each other in a sequence.

[0208] “Duplex” means two oligomeric compounds that are paired. In certain embodiments, the two oligomeric compounds are paired via hybridization of complementary nucleobases.

[0209] “Fully modified” in reference to a modified oligonucleotide means a modified oligonucleotide in which each sugar moiety is modified. “Uniformly modified” in reference to a modified oligonucleotide means a fully modified oligonucleotide in which each sugar moiety is the same. For example, the nucleosides of a uniformly modified oligo-

nucleotide can each have a 2'-MOE modification but different nucleobase modifications, and the internucleoside linkages may be different.

[0210] “Hybridization” means the pairing or annealing of complementary oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.

[0211] “Inhibiting the expression or activity” refers to a reduction or blockade of the expression or activity relative to the expression of activity in an untreated or control sample and does not necessarily indicate a total elimination of expression or activity.

[0212] “Internucleoside linkage” means a group or bond that forms a covalent linkage between adjacent nucleosides in an oligonucleotide. As used herein “modified internucleoside linkage” means any internucleoside linkage other than a naturally occurring, phosphate internucleoside linkage. Non-phosphate linkages are referred to herein as modified internucleoside linkages. “Phosphorothioate linkage” means a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom. A phosphorothioate internucleoside linkage is a modified internucleoside linkage.

[0213] “Linker-nucleoside” means a nucleoside that links, either directly or indirectly, an oligonucleotide to a conjugate moiety. Linker-nucleosides are located within the conjugate linker of an oligomeric compound. Linker-nucleosides are not considered part of the oligonucleotide portion of an oligomeric compound even if they are contiguous with the oligonucleotide.

[0214] “Non-bicyclic modified sugar” or “non-bicyclic modified sugar moiety” means a modified sugar moiety that comprises a modification, such as a substituent, that does not form a bridge between two atoms of the sugar to form a second ring.

[0215] “Linked nucleosides” are nucleosides that are connected in a continuous sequence (i.e. no additional nucleosides are present between those that are linked).

[0216] “Mismatch” or “non-complementary” means a nucleobase of a first oligonucleotide that is not complementary with the corresponding nucleobase of a second oligonucleotide or target nucleic acid when the first and second oligomeric compound are aligned.

[0217] “MOE” means methoxyethyl. “2'-MOE” means a $-OCH_2CH_2OCH_3$ group at the 2' position of a furanosyl ring.

[0218] “Motif” means the pattern of unmodified and/or modified sugar moieties, nucleobases, and/or internucleoside linkages, in an oligonucleotide.

[0219] “Naturally occurring” means found in nature.

[0220] “Nucleobase” means an unmodified nucleobase or a modified nucleobase. As used herein an “unmodified nucleobase” is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). As used herein, a “modified nucleobase” is a group of atoms other than unmodified A, T, C, U, or G capable of pairing with at least one unmodified nucleobase. A universal base is a modified nucleobase that can pair with any one of the five unmodified nucleobases. As used herein, “nucleobase sequence” means the order of

contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or internucleoside linkage modification.

[0221] “Nucleoside” means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each, independently, unmodified or modified. As used herein, “modified nucleoside” means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety.

[0222] Modified nucleosides include abasic nucleosides, which lack a nucleobase.

[0223] “Oligomeric compound” means a compound consisting of an oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group.

[0224] “Oligonucleotide” means a strand of linked nucleosides connected via internucleoside linkages, wherein each nucleoside and internucleoside linkage may be modified or unmodified. Unless otherwise indicated, oligonucleotides consist of 8-50 linked nucleosides. As used herein, “modified oligonucleotide” means an oligonucleotide, wherein at least one nucleoside or internucleoside linkage is modified. As used herein, “unmodified oligonucleotide” means an oligonucleotide that does not comprise any nucleoside modifications or internucleoside modifications.

[0225] “Pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an animal. Certain such carriers enable pharmaceutical compositions to be formulated as, for example, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspension and lozenges for the oral ingestion by a subject. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile water; sterile saline; or sterile buffer solution.

[0226] “Pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts of compounds, such as oligomeric compounds, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0227] “Pharmaceutical composition” means a mixture of substances suitable for administering to a subject. For example, a pharmaceutical composition may comprise an antisense compound and a sterile aqueous solution. In certain embodiments, a pharmaceutical composition shows activity in free uptake assay in certain cell lines.

[0228] “Phosphorus moiety” means a group of atoms comprising a phosphorus atom. In certain embodiments, a phosphorus moiety comprises a mono-, di-, or tri-phosphate, or phosphorothioate. In certain embodiments, a phosphorus moiety comprises a modified phosphate.

[0229] “Prodrug” means a therapeutic agent in a form outside the body that is converted to a different form within the body or cells thereof. Typically conversion of a prodrug within the body is facilitated by the action of an enzyme (e.g., endogenous or viral enzyme) or chemicals present in cells or tissues and/or by physiologic conditions.

[0230] “Single-stranded” in reference to an oligomeric compound means such a compound that is not paired with a second oligomeric compound to form a duplex. “Self-complementary” in reference to an oligonucleotide means an oligonucleotide that at least partially hybridizes to itself. A compound consisting of one oligomeric compound, wherein the oligonucleotide of the oligomeric compound is self-complementary, is a single-stranded compound. A single-

stranded antisense or oligomeric compound may be capable of binding to a complementary oligomeric compound to form a duplex, in which case it would no longer be single-stranded.

[0231] “Standard cell assay” means the assay described in Example 2 and reasonable variations thereof.

[0232] “Standard in vivo experiment” means the procedure described in Example 3 and reasonable variations thereof.

[0233] “Sugar moiety” means an unmodified sugar moiety or a modified sugar moiety. As used herein, “unmodified sugar moiety” means a 2'-OH(H) furanosyl moiety, as found in RNA (an “unmodified RNA sugar moiety”), or a 2'-H(H) moiety, as found in DNA (an “unmodified DNA sugar moiety”). Unmodified sugar moieties have one hydrogen at each of the 1', 3', and 4' positions, an oxygen at the 3' position, and two hydrogens at the 5' position. As used herein, “modified sugar moiety” or “modified sugar” means a modified furanosyl sugar moiety or a sugar surrogate. As used herein, modified furanosyl sugar moiety means a furanosyl sugar comprising a non-hydrogen substituent in place of at least one hydrogen of an unmodified sugar moiety. In certain embodiments, a modified furanosyl sugar moiety is a 2'-substituted sugar moiety. Such modified furanosyl sugar moieties include bicyclic sugars and non-bicyclic sugars. As used herein, “sugar surrogate” means a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide. Modified nucleosides comprising sugar surrogates can be incorporated into one or more positions within an oligonucleotide and such oligonucleotides are capable of hybridizing to complementary oligomeric compounds or nucleic acids.

[0234] “Target nucleic acid” means a naturally occurring, identified nucleic acid. In certain embodiments, target nucleic acids are endogenous cellular nucleic acids, including, but not limited to RNA transcripts, pre-mRNA, mRNA, microRNA. In certain embodiments, target nucleic acids are viral nucleic acids. In certain embodiments, target nucleic acids are nucleic acids that an antisense compound is designed to affect.

[0235] “Target region” means a portion of a target nucleic acid to which an antisense compound is designed to hybridize.

[0236] “Terminal group” means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide.

[0237] “Unlocked nucleic acid” means a nucleoside comprising an unlocked sugar moiety. As used herein, “unlocked sugar” or “unlocked sugar moiety” means a modified sugar moiety comprising no rings. In certain embodiments, one of the bonds that is part of the ring of a furanosyl moiety is broken in an unlocked sugar.

[0238] I. Certain Oligonucleotides

[0239] In certain embodiments, the invention provides oligonucleotides, which consist of linked nucleosides. Oligonucleotides may be unmodified oligonucleotides (RNA or DNA) or may be modified oligonucleotides. Modified oligonucleotides comprise at least one modification relative to unmodified RNA or DNA (i.e., comprise at least one modified nucleoside (comprising a modified sugar moiety and/or a modified nucleobase) and/or at least one modified internucleoside linkage).

[0240] A. Certain Modified Nucleosides

[0241] Modified nucleosides comprise a modified sugar moiety or a modified nucleobase or both a modified sugar moiety and a modified nucleobase.

[0242] 1. Certain Sugar Moieties

[0243] In certain embodiments, modified sugar moieties are non-bicyclic modified sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of other types of modified sugar moieties.

[0244] In certain embodiments, modified sugar moieties are non-bicyclic modified sugar moieties comprising a furanosyl ring with one or more acyclic substituent, including but not limited to substituents at the 2', 4', and/or 5' positions. In certain embodiments one or more acyclic substituent of non-bicyclic modified sugar moieties is branched. Examples of 2'-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2'-F, 2'-OCH₃ ("OMe" or "O-methyl"), and 2'-O(CH₂)₂OCH₃ ("MOE"). In certain embodiments, 2'-substituent groups are selected from among: halo, allyl, amino, azido, SH, CN, OCN, CF₃, OCF₃, O—C₁–C₁₀ alkoxy, O—C₁–C₁₀ substituted alkoxy, O—C₁–C₁₀ alkyl, O—C₁–C₁₀ substituted alkyl, S-alkyl, N(R_m)-alkyl, O-alkenyl, S-alkenyl, N(R_m)-alkenyl, O-alkynyl, S-alkynyl, N(R_m)-alkynyl, O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O(CH₂)₂ON(R_m)(R_n) or OCH₂C(=O)—N(R_m)(R_n), where each R_m and R_n is, independently, H, an amino protecting group, or substituted or unsubstituted C₁–C₁₀ alkyl, and the 2'-substituent groups described in Cook et al., U.S. Pat. No. 6,531,584; Cook et al., U.S. Pat. No. 5,859,221; and Cook et al., U.S. Pat. No. 6,005,087.

[0245] Certain embodiments of these 2'-substituent groups can be further substituted with one or more substituent groups independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl and alkynyl. Examples of 4'-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128. Examples of 5'-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 5'-methyl (R or S), 5'-vinyl, and 5'-methoxy. In certain embodiments, non-bicyclic modified sugars comprise more than one non-bridging sugar substituent, for example, 2'-F-5'-methyl sugar moieties and the modified sugar moieties and modified nucleosides described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836.

[0246] In certain embodiments, a 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group selected from: F, NH₂, N₃, OCF₃, OCH₃, O(CH₂)₃NH₂, CH₂CH=CH₂, OCH₂CH=CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂ON(R_m)(R_n), O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substituted acetamide (OCH₂C(=O)—N(R_m)(R_n)), where each R_m and R_n is, independently, H, an amino protecting group, or substituted or unsubstituted C₁–C₁₀ alkyl.

[0247] In certain embodiments, a 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group

selected from: F, OCF₃, OCH₃, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂ON(CH₃)₂, O(CH₂)₂O(CH₂)₂N(CH₃)₂, and OCH₂C(=O)—N(H)CH₃ ("NMA").

[0248] In certain embodiments, a 2'-substituted nucleoside or 2'-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2'-substituent group selected from: F, OCH₃, and OCH₂CH₂OCH₃.

[0249] Nucleosides comprising modified sugar moieties, such as non-bicyclic modified sugar moieties, may be referred to by the position(s) of the substitution(s) on the sugar moiety of the nucleoside. For example, nucleosides comprising 2'-substituted or 2'-modified sugar moieties are referred to as 2'-substituted nucleosides or 2'-modified nucleosides.

[0250] Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4' and the 2' furanose ring atoms. Examples of such 4' to 2' bridging sugar substituents include but are not limited to: 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂-O-2' ("LNA"), 4'-CH₂-S-2', 4'-(CH₂)₂-O-2' ("ENA"), 4'-CH(CH₃)-O-2' (referred to as "constrained ethyl" or "cEt" when in the S configuration), 4'-CH₂-O-CH₂-2', 4'-CH₂-N(R)-2', 4'-CH(CH₂OCH₃)-O-2' ("constrained MOE" or "cMOE") and analogs thereof (see, e.g., Seth et al., U.S. Pat. No. 7,399,845, Bhat et al., U.S. Pat. No. 7,569,686, Swayze et al., U.S. Pat. No. 7,741,457, and Swayze et al., U.S. Pat. No. 8,022,193), 4'-C(CH₃)(CH₃)-O-2' and analogs thereof (see, e.g., Seth et al., U.S. Pat. No. 8,278,283), 4'-CH₂-N(OCH₃)-2' and analogs thereof (see, e.g., Prakash et al., U.S. Pat. No. 8,278,425), 4'-CH₂-O-N(CH₃)-2' (see, e.g., Allerson et al., U.S. Pat. No. 7,696,345 and Allerson et al., U.S. Pat. No. 8,124,745), 4'-CH₂-C(H)(CH₃)-2' (see, e.g., Zhou, et al., *J. Org. Chem.*, 2009, 74, 118-134), 4'-CH₂-C(=CH₂)-2' and analogs thereof (see e.g., Seth et al., U.S. Pat. No. 8,278,426), 4'-C(R_aR_b)-N(R)-O-2', 4'-C(R_aR_b)-O-N(R)-2', 4'-CH₂-O-N(R)-2', and 4'-CH₂-N(R)-O-2', wherein each R, R_a, and R_b is, independently, H, a protecting group, or C₁–C₁₂ alkyl (see, e.g. Imanishi et al., U.S. Pat. No. 7,427,672).

[0251] In certain embodiments, such 4' to 2' bridges independently comprise from 1 to 4 linked groups independently selected from: —[C(R_a)(R_b)]_n—, —[C(R_a)(R_b)]_nO—, —C(R_a)=C(R_b)—, —C(R_a)=N—, —C(=NR_a)—, —C(=O)—, —C(=S)—, —O—, —Si(R_a)₂—, —S(=O)—, and —N(R_a)—;

[0252] wherein:

[0253] x is 0, 1, or 2;

[0254] n is 1, 2, 3, or 4;

[0255] each R_a and R_b is, independently, H, a protecting group, hydroxyl, C₁–C₁₂ alkyl, substituted C₁–C₁₂ alkyl, C₂–C₁₂ alkenyl, substituted C₂–C₁₂ alkenyl, C₂–C₁₂ alkynyl, substituted C₂–C₁₂ alkynyl, C₅–C₂₀ aryl, substituted C₅–C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅–C₇ alicyclic radical, substituted C₅–C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)—H), substituted acyl, CN, sulfonyl (S(=O)₂-J₁), or sulfoxyl (S(=O)-J₁); and


[0256] each J₁ and J₂ is, independently, H, C₁–C₁₂ alkyl, substituted C₁–C₁₂ alkyl, C₂–C₁₂ alkenyl, substituted C₂–C₁₂ alkenyl, C₂–C₁₂ alkynyl, substituted C₂–C₁₂ alkynyl, C₅–C₂₀ aryl, substituted C₅–C₂₀ aryl, acyl (C(=O)—H), substituted

acyl, a heterocycle radical, a substituted heterocycle radical, C_1 - C_{12} aminoalkyl, substituted C_1 - C_{12} aminoalkyl, or a protecting group.


[0257] Additional bicyclic sugar moieties are known in the art, see, for example: Freier et al., *Nucleic Acids Research*, 1997, 25(22), 4429-4443; Albaek et al., *J. Org. Chem.*, 2006, 71, 7731-7740; Singh et al., *Chem. Commun.*, 1998, 4, 455-456; Koshkin et al., *Tetrahedron*, 1998, 54, 3607-3630; Kumar et al., *Bioorg. Med. Chem. Lett.*, 1998, 8, 2219-2222; Singh et al., *J. Org. Chem.*, 1998, 63, 10035-10039; Srivastava et al., *J. Am. Chem. Soc.*, 20017, 129, 8362-8379; Wengel et al., U.S. Pat. No. 7,053,207; Imanishi et al., U.S. Pat. No. 6,268,490; Imanishi et al. U.S. Pat. No. 6,770,748; Imanishi et al., U.S. RE44,779; Wengel et al., U.S. Pat. No. 6,794,499; Wengel et al., U.S. Pat. No. 6,670,461; Wengel et al., U.S. Pat. No. 7,034,133; Wengel et al., U.S. Pat. No. 8,080,644; Wengel et al., U.S. Pat. No. 8,034,909; Wengel et al., U.S. Pat. No. 8,153,365; Wengel et al., U.S. Pat. No. 7,572,582; and Ramasamy et al., U.S. Pat. No. 6,525,191; Torsten et al., WO 2004/106356; Wengel et al., WO 1999/014226; Seth et al., WO 2007/134181; Seth et al., U.S. Pat. No. 7,547,684; Seth et al., U.S. Pat. No. 7,666,854; Seth et al., U.S. Pat. No. 8,088,746; Seth et al., U.S. Pat. No. 7,750,131; Seth et al., U.S. Pat. No. 8,030,467; Seth et al., U.S. Pat. No. 8,268,980; Seth et al., U.S. Pat. No. 8,546,556; Seth et al., U.S. Pat. No. 8,530,640; Migawa et al., U.S. Pat. No. 9,012,421; Seth et al., U.S. Pat. No. 8,501,805; and U.S. Patent Publication Nos. Allerson et al., US2008/0039618 and Migawa et al., US2015/0191727.

[0258] In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, an LNA nucleoside (described herein) may be in the α -L configuration or in the β -D configuration.

LNA (β -D-configuration) bridge = 4'-CH₂-O-2'



α -L-LNA (α -L-configuration) bridge = 4'-CH₂-O-2'




α -L-methyleneoxy (4'-CH₂-O-2') or α -L-LNA bicyclic nucleosides have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., *Nucleic Acids Research*, 2003, 21, 6365-6372). Herein, general descriptions of bicyclic nucleosides include both isomeric configurations. When the positions of specific bicyclic nucleosides (e.g., LNA or cEt) are identified in exemplified embodiments herein, they are in the β -D configuration, unless otherwise specified.

[0259] In certain embodiments, modified sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5'-substituted and 4'-2' bridged sugars).


[0260] In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the sugar moiety is replaced, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moieties also comprise bridging and/or non-bridging substituents as described herein. For example, certain sugar surrogates comprise a 4'-sulfur atom and a substitution at the 2'-position (see, e.g., Bhat et al., U.S. Pat. No. 7,875,733 and Bhat et al., U.S. Pat. No. 7,939,677) and/or the 5' position.

[0261] In certain embodiments, sugar surrogates comprise rings having other than 5 atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran ("THP"). Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include but are not limited to hexitol nucleic acid ("HNA"), anitol nucleic acid ("ANA"), manitol nucleic acid ("MNA") (see, e.g., Leumann, C.J. *Bioorg. & Med. Chem.* 2002, 10, 841-854), fluoro HNA:

F-HNA



("F-HNA", see e.g. Swayze et al., U.S. Pat. No. 8,088,904; Swayze et al., U.S. Pat. No. 8,440,803; Swayze et al., U.S. Pat. No. 8,796,437; and Swayze et al., U.S. Pat. No. 9,005,906; F-HNA can also be referred to as a F-THP or 3'-fluoro tetrahydropyran), and nucleosides comprising additional modified THP compounds having the formula:



wherein, independently, for each of said modified THP nucleoside:


[0262] Bx is a nucleobase moiety;

[0263] T₃ and T₄ are each, independently, an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide or one of T₃ and T₄ is an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5' or 3'-terminal group; q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl,

substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and [0264] each of R₁ and R₂ is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(=X)J₁, OC(=X)NJ₁J₂, NJ₃C(=X)NJ₁J₂, and CN, wherein X is O, S or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

[0265] In certain embodiments, modified THP nucleosides are provided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other than H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is methyl. In certain embodiments, modified THP nucleosides are provided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ is F and R₂ is H, in certain embodiments, R₁ is methoxy and R₂ is H, and in certain embodiments, R₁ is methoxyethoxy and R₂ is H.

[0266] In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example, nucleosides comprising morpholino sugar moieties and their use in oligonucleotides have been reported (see, e.g., Braasch et al., *Biochemistry*, 2002, 41, 4503-4510 and Summerton et al., U.S. Pat. No. 5,698,685; Summerton et al., U.S. Pat. No. 5,166,315; Summerton et al., U.S. Pat. No. 5,185,444; and Summerton et al., U.S. Pat. No. 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following structure:



In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modified morpholinos.”

[0267] In certain embodiments, sugar surrogates comprise acyclic moieties. Examples of nucleosides and oligonucleotides comprising such acyclic sugar surrogates include but are not limited to: peptide nucleic acid (“PNA”), acyclic butyl nucleic acid (see, e.g., Kumar et al., *Org. Biomol. Chem.*, 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., WO2011/133876. Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used in modified nucleosides).

[0268] 2. Certain Modified Nucleobases

[0269] In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising an unmodified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside that does not comprise a nucleobase, referred to as an abasic nucleoside.

[0270] In certain embodiments, modified nucleobases are selected from: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and O-6 substituted purines. In certain embodiments, modified nucleobases are selected from:

2-aminopropyladenine, 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl (—C≡C—CH₃) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in Merigan et al., U.S. Pat. No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613; Sanghvi, Y. S., Chapter 15, *Antisense Research and Applications*, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288; and those disclosed in Chapters 6 and 15, *Antisense Drug Technology*, Crooke S. T., Ed., CRC Press, 2008, 163-166 and 442-443.

[0271] Publications that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, Manohara et al., US2003/0158403; Manoharan et al., US2003/0175906; Dinh et al., U.S. Pat. No. 4,845,205; Spielvogel et al., U.S. Pat. No. 5,130,302; Rogers et al., U.S. Pat. No. 5,134,066; Bischofberger et al., U.S. Pat. No. 5,175,273; Urdea et al., U.S. Pat. No. 5,367,066; Benner et al., U.S. Pat. No. 5,432,272; Matteucci et al., U.S. Pat. No. 5,434,257; Gmeiner et al., U.S. Pat. No. 5,457,187; Cook et al., U.S. Pat. No. 5,459,255; Froehler et al., U.S. Pat. No. 5,484,908; Matteucci et al., U.S. Pat. No. 5,502,177; Hawkins et al., U.S. Pat. No. 5,525,711; Haralambidis et al., U.S. Pat. No. 5,552,540; Cook et al., U.S. Pat. No. 5,587,469; Froehler et al., U.S. Pat. No. 5,594,121; Switzer et al., U.S. Pat. No. 5,596,091; Cook et al., U.S. Pat. No. 5,614,617; Froehler et al., U.S. Pat. No. 5,645,985; Cook et al., U.S. Pat. No. 5,681,941; Cook et al., U.S. Pat. No. 5,811,534; Cook et al., U.S. Pat. No. 5,750,692; Cook et al., U.S. Pat. No. 5,948,903; Cook et al., U.S. Pat. No. 5,587,470; Cook et al., U.S. Pat. No. 5,457,191; Matteucci et al., U.S. Pat. No. 5,763,588; Froehler et al., U.S. Pat. No. 5,830,653; Cook et al., U.S. Pat. No. 5,808,027; Cook et al., 6,166,199; and Matteucci et al., U.S. Pat. No. 6,005,096.

[0272] B. Certain Modified Internucleoside Linkages

[0273] In certain embodiments, nucleosides of modified oligonucleotides may be linked together using any internucleoside linkage. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus-containing internucleoside linkages include but are not limited to phospho-

phates, which contain a phosphodiester bond ("P=O") (also referred to as unmodified or naturally occurring linkages), phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates ("P=S"), and phosphorodithioates ("HS-P=S"). Representative non-phosphorus containing internucleoside linking groups include but are not limited to methylenemethylimino ($-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$), thiodiester, thionocarbamate ($-\text{O}-\text{C}(=\text{O})(\text{NH})-\text{S}-$); siloxane ($-\text{O}-\text{SiH}_2-\text{O}-$); and N,N'-dimethylhydrazine ($-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-$). Modified internucleoside linkages, compared to naturally occurring phosphate linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. In certain embodiments, internucleoside linkages having a chiral atom can be prepared as a racemic mixture, or as separate enantiomers. Representative chiral internucleoside linkages include but are not limited to alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art.

[0274] Neutral internucleoside linkages include, without limitation, phosphotriesters, methylphosphonates, MMI (3'- $\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-5'$), amide-3 (3'- $\text{CH}_2-\text{C}(=\text{O})-\text{N}(\text{H})-5'$), amide-4 (3'- $\text{CH}_2-\text{N}(\text{H})-\text{C}(=\text{O})-5'$), formacetal (3'- $\text{O}-\text{CH}_2-\text{O}-5'$), methoxypropyl, and thioformacetal (3'- $\text{S}-\text{CH}_2-\text{O}-5'$). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: *Carbohydrate Modifications in Antisense Research*; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH_2 component parts.

[0275] C. Certain Motifs

[0276] In certain embodiments, modified oligonucleotides comprise one or more modified nucleoside comprising a modified sugar. In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more modified internucleoside linkage. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and/or internucleoside linkages of a modified oligonucleotide define a pattern or motif. In certain embodiments, the patterns of sugar moieties, nucleobases, and internucleoside linkages are each independent of one another. Thus, a modified oligonucleotide may be described by its sugar motif, nucleobase motif and/or internucleoside linkage motif (as used herein, nucleobase motif describes the modifications to the nucleobases independent of the sequence of nucleobases).

[0277] In certain embodiments, the present invention provides oligomeric compounds comprising one or more regions having a particular nucleoside motif. In certain embodiments, the 5'-terminal group and 5'-terminal nucleoside of an oligomeric compound of the present invention comprises a compound of Formula II, IIa, IIb, or IIc.

[0278] 1. Certain Sugar Motifs

[0279] In certain embodiments, oligonucleotides comprise one or more type of modified sugar and/or unmodified sugar moiety arranged along the oligonucleotide or region thereof in a defined pattern or sugar motif. In certain instances, such

sugar motifs include but are not limited to any of the sugar modifications discussed herein.

[0280] In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif. In such embodiments, each nucleoside of the fully modified region of the modified oligonucleotide comprises a modified sugar moiety. In certain such embodiments, each nucleoside of the entire modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif, wherein each nucleoside within the fully modified region comprises the same modified sugar moiety, referred to herein as a uniformly modified sugar motif. In certain embodiments, a fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside of a uniformly modified comprises the same 2'-modification. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif, wherein the fully modified sugar motif is an alternating motif. In certain such embodiments, the sugar moieties of the alternating motif alternate between 2'-OMe and 2'-F.

[0281] 2. Certain Nucleobase Motifs

[0282] In certain embodiments, oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines.

[0283] In certain embodiments, modified oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3'-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 3'-end of the oligonucleotide. In certain embodiments, the block is at the 5'-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 5'-end of the oligonucleotide.

[0284] 3. Certain Internucleoside Linkage Motifs

[0285] In certain embodiments, oligonucleotides comprise modified and/or unmodified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, essentially each internucleoside linking group is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is independently selected from a phosphorothioate and phosphate internucleoside linkage. In certain embodiments, the oligonucleotide comprises a region of alternating internucleoside linkages. In certain such embodiments, the alternating internucleoside linkages are phosphorothioate and phosphate internucleoside linkages. In certain embodiments, the terminal internucleoside linkages are modified.

[0286] 4. Certain Alternating Motifs

[0287] In certain embodiments, oligonucleotides of the present invention comprise one or more regions of alternat-

ing modifications. In certain embodiments, oligonucleotides comprise one or more regions of alternating nucleoside modifications. In certain embodiments, oligonucleotides comprise one or more regions of alternating linkage modifications. In certain embodiments, oligonucleotides comprise one or more regions of alternating nucleoside and linkage modifications.

[0288] In certain embodiments, oligonucleotides of the present invention comprise one or more regions of alternating 2'-F modified nucleosides and 2'-OMe modified nucleosides. In certain such embodiments, such regions of alternating 2'-F modified and 2'-OMe modified nucleosides also comprise alternating linkages. In certain such embodiments, the linkages at the 3' position of the 2'-F modified nucleosides are phosphorothioate linkages. In certain such embodiments, the linkages at the 3' position of the 2'-OMe nucleosides are phosphate linkages.

[0289] In certain embodiments, oligomeric compounds comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 regions of alternating modifications. Such regions may be contiguous or may be interrupted by differently modified nucleosides or linkages.

[0290] In certain embodiments, alternating motifs have a pattern in which every other moiety is a first type or a second type, e.g., ABABA, etc. In certain embodiments, alternating motifs have a pattern in which the moieties of a first type and the moieties of a second type alternate in varied numbers. For example, oligonucleotide of the present invention may include one or more regions of any of the following alternating motifs:

AABBAA;

ABBABB;

AABAAB;

ABBABAABB;

ABABAA;

AABABAB;

ABABAA;

ABBAABBABABAA;

BABBAABBABABAA; or

ABABBAABBABABAA;

[0291] wherein A is a nucleoside or internucleoside linkage of a first type and B is a nucleoside or internucleoside linkage of a second type. In certain embodiments, A and B are each selected from 2'-F, 2'-OMe, BNA, DNA, and MOE.

[0292] In certain embodiments, compounds comprising such an alternating motif also comprise a 5' terminal group and 5'-terminal nucleoside of formula II, IIa, IIb, or IIc.

[0293] 5. Combinations of Motifs

[0294] It is to be understood, that certain of the above described motifs and modifications may be combined. Since a motif may comprise only a few nucleosides, a particular oligonucleotide may comprise two or more motifs. Oligonucleotides having any of the various nucleoside motifs described herein, may have any linkage motif. The lengths of the regions defined by a nucleoside motif and that of a linkage motif need not be the same. For example, non-

limiting nucleoside motifs and sequence motifs are combined to show five examples in the table below. The first column of the table lists nucleosides and linkages by position from N1 (the 5'-end) to N20 (the 20th position from the 5'-end). In certain embodiments, oligonucleotides of the present invention are longer than 20 nucleosides (the table is merely exemplary). Certain positions in the table recite the nucleoside or linkage "none" indicating that the oligonucleotide has no nucleoside at that position.

Pos	A	B	C	D	E
N1	Formula II, IIa, IIb, or IIc	Formula II, IIa, IIb, or IIc	Formula II, IIa, IIb, or IIc	Formula II, IIa, IIb, or IIc	Formula II, IIa, IIb, or IIc
L1	PS	PS	PS	PS	PO
N2	2'-F	2'-F	2'-F	2'-OMe	MOE
L2	PS	PS	PS	PO	PS
N3	2'-OMe	2'-F	2'-F	2'-F	2'-F
L3	PO	PS	PS	PS	PS
N4	2'-F	2'-F	2'-F	2'-OMe	2'-F
L4	PS	PS	PS	PO	PS
N5	2'-OMe	2'-F	2'-F	2'-F	2'-OMe
L5	PO	PS	PS	PS	PO
N6	2'-F	2'-OMe	2'-F	2'-OMe	2'-OMe
L6	PS	PO	PS	PO	PO
N7	2'-OMe	2'-OMe	2'-F	2'-F	2'-OMe
L7	PO	PO	PS	PS	PO
N8	2'-F	2'-F	2'-F	2'-OMe	2'-F
L8	PS	PS	PS	PO	PS
N9	2'-OMe	2'-F	2'-F	2'-F	2'-F
L9	PO	PS	PS	PS	PS
N10	2'-F	2'-OMe	2'-F	2'-OMe	2'-OMe
L10	PS	PO	PS	PO	PO
N11	2'-OMe	2'-OMe	2'-F	2'-F	2'-OMe
L11	PO	PO	PS	PS	PO
N12	2'-F	2'-F	2'-F	2'-F	2'-F
L12	PS	PS	PS	PO	PS
N13	2'-OMe	2'-F	2'-F	2'-F	2'-F
L13	PO	PS	PS	PS	PS
N14	2'-F	2'-OMe	2'-F	2'-F	2'-F
L14	PS	PS	PS	PS	PS
N15	2'-OMe	2'-OMe	2'-F	2'-F	2'-MOE
L15	PS	PS	PS	PS	PS
N16	2'-F	2'-OMe	2'-F	2'-F	2'-MOE
L16	PS	PS	PS	PS	PS
N17	2'-OMe	2'-MOE U	2'-F	2'-F	2'-MOE
L17	PS	PS	PS	PS	None
N18	2'-F	2'-MOE U	2'-F	2'-OMe	None
L18	PS	None	PS	PS	None
N19	2'-MOE U	None	2'-MOE U	2'-MOE A	None
L19	PS	None	PS	PS	None
N20	2'-MOE U	None	2'-MOE U	2'-MOE A	None

In the above, non-limiting examples:

[0295] Column A represents an oligomeric compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein the oligomeric compound comprises: a 5'-terminal group and 5'-terminal nucleoside of Formula II, IIa, IIb, or IIc; a region of alternating nucleosides; a region of alternating linkages; two 3'-terminal MOE nucleosides, each of which comprises a uracil base; and a region of six phosphorothioate linkages at the 3'-end.

[0296] Column B represents an oligomeric compound comprising a modified oligonucleotide consisting of 18 linked nucleosides, wherein the oligomeric compound comprises: a 5'-terminal group and 5'-terminal nucleoside of Formula II, IIa, IIb, or IIc; two 3'-terminal MOE nucleosides, each of which comprises a uracil base; and a region of six phosphorothioate linkages at the 3'-end.

[0297] Column C represents an oligomeric compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein the oligomeric compound comprises: a 5'-terminal group and 5'-terminal nucleoside of Formula II, IIa, IIb, or IIc; a region of uniformly modified 2'-F nucleosides; two 3'-terminal MOE nucleosides, each of which comprises a uracil base; and wherein each internucleoside linkage is a phosphorothioate linkage.

[0298] Column D represents an oligomeric compound comprising a modified oligonucleotide consisting of 20 linked nucleosides, wherein the oligomeric compound comprises: a 5'-terminal group and 5'-terminal nucleoside of Formula II, IIa, IIb, or IIc; a region of alternating 2'-OMe/2'-F nucleosides; a region of uniform 2'-F nucleosides; a region of alternating phosphorothioate/phosphodiester linkages; two 3'-terminal MOE nucleosides, each of which comprises an adenine base; and a region of six phosphorothioate linkages at the 3'-end.

[0299] Column E represents an oligomeric compound comprising a modified oligonucleotide consisting of 17 linked nucleosides, wherein the oligomeric compound comprises: a 5'-terminal group and 5'-terminal nucleoside of Formula II, IIa, IIb, or IIc; three 3'-terminal MOE nucleosides.

[0300] The above examples are provided solely to illustrate how the described motifs may be used in combination and are not intended to limit the invention to the particular combinations or the particular modifications used in illustrating the combinations. Further, specific examples herein, including, but not limited to those in the above table are intended to encompass more generic embodiments. For example, column A in the above table exemplifies a region of alternating 2'-OMe and 2'-F nucleosides. Thus, that same disclosure also exemplifies a region of alternating different 2'-modifications. It also exemplifies a region of alternating 2'-O-alkyl and 2'-halogen nucleosides. It also exemplifies a region of alternating differently modified nucleosides. All of the examples throughout this specification contemplate such generic interpretation. It is also noted that the lengths of oligomeric compounds, such as those exemplified in the above tables, can be easily manipulated by lengthening or shortening one or more of the described regions, without disrupting the motif.

[0301] D. Certain Lengths

[0302] In certain embodiments, oligonucleotides (including modified oligonucleotides) can have any of a variety of ranges of lengths. In certain embodiments, oligonucleotides consist of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that $X \leq Y$. For example, in certain embodiments, oligonucleotides consist of 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15

to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 27, 19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides

[0303] E. Certain Modified Oligonucleotides

[0304] In certain embodiments, the above modifications and motifs (sugar, nucleobase, internucleoside linkage) are incorporated into a modified oligonucleotide. In certain embodiments, modified oligonucleotides are characterized by their modification motifs and overall lengths. In certain embodiments, such parameters are each independent of one another. Thus, unless otherwise indicated, each internucleoside linkage of an oligonucleotide having a fully modified sugar motif may be modified or unmodified and may or may not follow the modification pattern of the sugar modifications. Likewise, such fully modified sugar motifs may comprise one or more modified nucleobase independent of the pattern of the sugar modifications. Furthermore, in certain instances, an oligonucleotide is described by an overall length or range and by lengths or length ranges of two or more regions (e.g., a regions of nucleosides having specified sugar modifications), in such circumstances it may be possible to select numbers for each range that result in an oligonucleotide having an overall length falling outside the specified range. In such circumstances, both elements must be satisfied. For example, in certain embodiments, a modified oligonucleotide consists of 15-20 linked nucleosides and has a sugar motif consisting of three regions, A, B, and C, wherein region A consists of 2-6 linked nucleosides having a specified sugar motif, region B consists of 6-10 linked nucleosides having a specified sugar motif, and region C consists of 2-6 linked nucleosides having a specified sugar motif. Such embodiments do not include modified oligonucleotides where A and C each consist of 6 linked nucleosides and B consists of 10 linked nucleosides (even though those numbers of nucleosides are permitted within the requirements for A, B, and C) because the overall length of such oligonucleotide is 22, which exceeds the upper limit of the overall length of the modified oligonucleotide (20). Herein, if a description of an oligonucleotide is silent with respect to one or more parameter, such parameter is not limited. Thus, a modified oligonucleotide described only as having a fully modified sugar motif without further description may have any length, internucleoside linkage motif, and nucleobase motif. Unless otherwise indicated, all modifications are independent of nucleobase sequence.

[0305] F. Nucleobase Sequence

[0306] In certain embodiments, oligonucleotides (unmodified or modified oligonucleotides) are further described by

their nucleobase sequence. In certain embodiments oligonucleotides have a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain such embodiments, a region of an oligonucleotide has a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain embodiments, the nucleobase sequence of a region or entire length of an oligonucleotide is at least 70%, at least 80%, at least 90%, at least 95%, or 100% complementary to the second oligonucleotide or nucleic acid, such as a target nucleic acid.

[0307] II. Certain Oligomeric Compounds

[0308] In certain embodiments, oligomeric compounds of the present invention are single-stranded. In certain embodiments, an oligomeric compound of the present invention hybridizes to a second oligomeric compound and forms a duplex. In certain embodiments, such duplexes are double-stranded antisense compounds. Such double-stranded antisense compounds comprise a first oligomeric compound having a region complementary to a target nucleic acid and a second oligomeric compound having a region complementary to the first oligomeric compound. The first oligomeric compound of such double-stranded antisense compounds typically comprises or consists of a modified oligonucleotide and optionally a terminal group or conjugate group. The oligonucleotide of the second oligomeric compound of such double-stranded antisense compound may be modified or unmodified. Either or both oligomeric compounds of a double-stranded antisense compound may comprise a terminal group or a conjugate group. The oligomeric compounds of double-stranded antisense compounds may include non-complementary overhanging nucleosides. Although certain oligomeric compounds of the present invention have particular use as single-stranded compounds, such compounds may also be paired with a second oligomeric compound to create a duplex. In such embodiments, the second oligomeric compound of the duplex may or may not be an oligomeric compound of the present invention.

[0309] In certain embodiments, oligomeric compounds of the present invention are single-stranded compounds that interact with a member of the RNA-induced silencing complex (RISC) and/or other member of the RNA interference pathway. Certain 5'-terminal groups, such as phosphorus moieties, described herein are suited for use in such single-stranded oligomeric compounds. In certain embodiments, 5'-terminal groups and 5'-terminal nucleosides of the present invention are resistant to nucleases. In certain embodiments, the motifs of the present invention are particularly suited for use in single-stranded oligomeric compounds.

[0310] In certain embodiments, the invention provides oligomeric compounds, which consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups consist of one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2'-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3' and/or 5'-end of

oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3'-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5'-end of oligonucleotides.

[0311] Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphorus moieties (both unmodified phosphorus moieties and modified phosphorus moieties), protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.

[0312] A. Certain Conjugate Groups

[0313] In certain embodiments, oligonucleotides are covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937), a tocopherol group (Nishina et al., *Molecular Therapy Nucleic Acids*, 2015, 4, e220; and Nishina et al., *Molecular Therapy*, 2008, 16, 734-740), or a GalNAc cluster (e.g., WO2014/179620).

[0314] 1. Conjugate Moieties

[0315] Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes. In certain embodiments, lipid conjugates include palmityl, C₂₂ alkyl, C₂₀ alkyl, C₁₆ alkyl, C₁₀ alkyl, and C₈ alkyl.

[0316] In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, war-

farin, phenylbutazone, ibuprofen, suprofen, fen-bufen, keto-profen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

[0317] 2. Conjugate Linkers

[0318] Conjugate moieties are attached to oligonucleotides through conjugate linkers. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

[0319] In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.

[0320] In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

[0321] Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexanecarboxylate (SMCC) and 6-aminohexanoic acid (AHX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C_1 - C_{10} alkyl, substituted or unsubstituted C_2 - C_{10} alkenyl or substituted or unsubstituted C_2 - C_{10} alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

[0322] In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, conjugate linkers comprise 2-5 linker-nucleosides. In certain embodiments, conjugate linkers comprise exactly 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise the TCA motif. In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides

are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.

[0323] Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid. For example, an oligomeric compound may comprise (1) a modified oligonucleotide consisting of 8-30 nucleosides and (2) a conjugate group comprising 1-10 linker-nucleosides that are contiguous with the nucleosides of the modified oligonucleotide. The total number of contiguous linked nucleosides in such an oligomeric compound is more than 30. Alternatively, an oligomeric compound may comprise a modified oligonucleotide consisting of 8-30 nucleosides and no conjugate group. The total number of contiguous linked nucleosides in such an oligomeric compound is no more than 30. Unless otherwise indicated conjugate linkers comprise no more than 10 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 5 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 2 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 1 linker-nucleoside.

[0324] In certain embodiments, it is desirable for a conjugate group to be cleaved from the oligonucleotide. For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate linkers may comprise one or more cleavable moieties. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

[0325] In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a car-

bamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group.

[0326] In certain embodiments, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such embodiments, the one or more linker-nucleosides are linked to one another and/or to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2'-deoxy nucleoside that is attached to either the 3' or 5'-terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2'-deoxyadenosine.

[0327] III. Certain Antisense Activities

[0328] In certain embodiments, the present invention provides antisense compounds, which comprise or consist of an oligomeric compound comprising an antisense oligonucleotide, having a nucleobase sequence complementary to that of a target nucleic acid. In certain embodiments, oligomeric compounds of antisense compounds are capable of hybridizing to a target nucleic acid, resulting in at least one antisense activity. In certain embodiments, antisense compounds selectively affect one or more target nucleic acid. Such selective antisense compounds comprises a nucleobase sequence that hybridizes to one or more target nucleic acid, resulting in one or more desired antisense activity and does not hybridize to one or more non-target nucleic acid or does not hybridize to one or more non-target nucleic acid in such a way that results in significant undesired antisense activity.

[0329] In certain embodiments, the invention provides compounds and methods for antisense activity in a cell. In certain embodiments, the cell is in an animal. In certain embodiments, the animal is a human. In certain embodiments, the invention provides methods of administering a compound of the present invention to an animal to modulate one or more target nucleic acid.

[0330] In certain antisense activities, hybridization of an antisense compound to a target nucleic acid results in recruitment of a protein that cleaves the target nucleic acid. For example, certain antisense compounds or a portion of an antisense compound is loaded into an RNA-induced silencing complex (RISC), ultimately resulting in cleavage of the target nucleic acid.

[0331] In certain embodiments, hybridization of an antisense compound to a target nucleic acid does not result in cleavage of the target nucleic acid. In certain such embodiments, hybridization of the antisense compound to the target nucleic acid results in inhibition of formation of aggregates or foci that comprise the target nucleic acid. In certain embodiments, hybridization of the antisense compound to the target nucleic acid results in alteration of splicing of the target nucleic acid. In certain embodiments, hybridization of an antisense compound to a target nucleic acid results in inhibition of a binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain such embodiments, hybridization of an antisense compound to a target nucleic acid results in alteration of translation of the target nucleic acid.

[0332] Antisense activities may be observed directly or indirectly. In certain embodiments, observation or detection of an antisense activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid, a change in the ratio of splice variants of a nucleic acid or protein, a change in the number of aggregates or foci comprising the target nucleic acid, and/or a phenotypic change in a cell or animal.

[0333] IV. Certain Target Nucleic Acids

[0334] In certain embodiments, antisense compounds comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid is a C9orf72 pre-mRNA. In certain embodiments, the C9orf72 pre-mRNA is a sense transcript. In certain embodiments, the C9orf72 pre-mRNA is an antisense transcript.

[0335] In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from: an mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, the target RNA is an mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron. In certain embodiments, the target region is completely within an intron.

[0336] In certain embodiments, the target nucleic acid is a non-coding RNA. In certain such embodiments, the target non-coding RNA is selected from: a long-non-coding RNA, a short non-coding RNA, an intronic RNA molecule, a snoRNA, a scaRNA, a microRNA (including pre-microRNA and mature microRNA), a ribosomal RNA, and promoter directed RNA. In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA. In certain embodiments, the target nucleic acid is a nucleic acid other than a mature mRNA or a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than a microRNA. In certain embodiments, the target nucleic acid is a non-coding RNA other than a microRNA or an intronic region of a pre-mRNA. In certain embodiments, the target nucleic acid is a long non-coding RNA. In certain embodiments, the target nucleic acid is a non-coding RNA associated with splicing of other pre-mRNAs. In certain embodiments, the target nucleic acid is a nuclear-retained non-coding RNA.

[0337] In certain embodiments, antisense compounds described herein are complementary to a target nucleic acid comprising a single-nucleotide polymorphism (SNP). In certain such embodiments, the antisense compound is capable of modulating expression of one allele of the SNP-containing target nucleic acid to a greater or lesser extent than it modulates another allele. In certain embodiments, an antisense compound hybridizes to a (SNP)-containing target nucleic acid at the single-nucleotide polymorphism site.

[0338] In certain embodiments, antisense compounds are at least partially complementary to more than one target nucleic acid. For example, antisense compounds of the present invention may mimic microRNAs, which typically bind to multiple targets.

[0339] A. Complementarity/Mismatches to the Target Nucleic Acid

[0340] In certain embodiments, antisense compounds comprise antisense oligonucleotides that are complementary to the target nucleic acid over the entire length of the oligonucleotide. In certain embodiments, such oligonucleotides are 99% complementary to a C9orf72 transcript. In certain embodiments, such oligonucleotides are 95% complementary to a C9orf72 transcript. In certain embodiments, such oligonucleotides are 90% complementary to a C9orf72 transcript. In certain embodiments, such oligonucleotides are 85% complementary to a C9orf72 transcript. In certain embodiments, such oligonucleotides are 80% complementary to a C9orf72 transcript. In certain embodiments, antisense oligonucleotides are at least 80% complementary to a C9orf72 transcript over the entire length of the oligonucleotide and comprise a region that is 100% or fully complementary to a C9orf72 transcript. In certain such embodiments, the region of full complementarity is from 6 to 20 nucleobases in length. In certain such embodiments, the region of full complementarity is from 10 to 18 nucleobases in length. In certain such embodiments, the region of full complementarity is from 18 to 20 nucleobases in length.

[0341] In certain embodiments, the oligonucleotides of antisense compounds comprise one or more mismatched nucleobases relative to the target nucleic acid, e.g., a C9orf72 transcript. In certain such embodiments, antisense activity against the target is reduced by such mismatch, but activity against a non-target is reduced by a greater amount. Thus, in certain such embodiments selectivity of the antisense compound is improved. In certain embodiments, antisense activity against the target is increased by such mismatch. In certain such embodiments, the position or positions of the mismatch affect the antisense activity of the compound. In certain such embodiments, the mismatch is at position 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, and/or 1 from the 5'-end of the oligonucleotide. In certain embodiments, the oligonucleotides of antisense compounds comprise two or more mismatches relative to the target nucleic acid.

[0342] V. Certain Pharmaceutical Compositions

[0343] In certain embodiments, the present invention provides pharmaceutical compositions comprising one or more antisense compound, oligomeric compound, and/or a salt thereof. In certain such embodiments, the pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more antisense compound. In certain embodiments, such pharmaceutical composition consists of a sterile saline solution and one or more antisense compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one antisense compound and sterile water. In certain embodiments, the sterile water is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more antisense compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more antisense compound and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical grade PBS.

[0344] In certain embodiments, pharmaceutical compositions comprise one or more antisense compound and one or more excipients. In certain such embodiments, excipients are selected from water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose and polyvinylpyrrolidone.

[0345] In certain embodiments, antisense compounds may be admixed with pharmaceutically acceptable active and/or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions depend on a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

[0346] In certain embodiments, pharmaceutical compositions comprising an antisense compound encompass any pharmaceutically acceptable salts of the antisense compound, esters of the antisense compound, or salts of such esters. In certain embodiments, pharmaceutical compositions comprising antisense compounds comprising one or more antisense oligonucleotide, upon administration to an animal, including a human, are capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. In certain embodiments, prodrugs comprise one or more conjugate group attached to an oligonucleotide, wherein the conjugate group is cleaved by endogenous nucleases within the body.

[0347] Lipid moieties have been used in nucleic acid therapies in a variety of methods. In certain such methods, the nucleic acid, such as an antisense compound, is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In certain methods, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to a particular cell or tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to fat tissue. In certain embodiments, a lipid moiety is selected to increase distribution of a pharmaceutical agent to muscle tissue.

[0348] In certain embodiments, pharmaceutical compositions comprise a delivery system. Examples of delivery systems include, but are not limited to, liposomes and emulsions. Certain delivery systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobic compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.

[0349] In certain embodiments, pharmaceutical compositions comprise one or more tissue-specific delivery molecules designed to deliver the one or more pharmaceutical agents of the present invention to specific tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody.

[0350] In certain embodiments, pharmaceutical compositions comprise a co-solvent system. Certain of such co-solvent systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent

systems are used for hydrophobic compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute ethanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/v polyethylene glycol 300. The proportions of such co-solvent systems may be varied considerably without significantly altering their solubility and toxicity characteristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

[0351] In certain embodiments, pharmaceutical compositions are prepared for oral administration. In certain embodiments, pharmaceutical compositions are prepared for intrathecal administration. In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subcutaneous, intramuscular, intrathecal etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. In certain embodiments, other ingredients are included (e.g., ingredients that aid in solubility or serve as preservatives). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilic solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, and liposomes. Aqueous injection suspensions may contain.

Nonlimiting Disclosure and Incorporation by Reference

[0352] All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, GenBank accession numbers, and treatises, are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety. While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, such examples serve only to illustrate the compounds described herein and are not intended to limit the same.

[0353] Although the sequence listing accompanying this filing identifies each sequence as either "RNA" or "DNA" as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as "RNA" or "DNA" to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2'-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2'-OH in place of one 2'-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) in place of a uracil of RNA). Accord-

ingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence "ATCGATCG" encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence "AUCGAUCG" and those having some DNA bases and some RNA bases such as "AUCGATCG" and oligomeric compounds having other modified nucleobases, such as "AT^mCGAUCG," wherein MC indicates a cytosine base comprising a methyl group at the 5-position.

[0354] Certain compounds described herein (e.g., modified oligonucleotides) have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as α or β such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Included in the compounds provided herein are all such possible isomers, including their racemic and optically pure forms, unless specified otherwise. Likewise, all cis- and trans-isomers, E and Z isomers, and tautomeric forms are also included unless otherwise indicated. Unless otherwise indicated, compounds described herein are intended to include corresponding salt forms.

[0355] The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the ¹H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to: ²H or ³H in place of ¹H, ¹³C or ¹⁴C in place of ¹²C, ¹⁵N in place of ¹⁴N, ¹⁷O or ¹⁸O in place of ¹⁶O, and ³³S, ³⁴S, ³⁵S, or ³⁶S in place of ³²S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool. In certain embodiments, radioactive isotopic substitutions may make the compound suitable for research or diagnostic purposes such as imaging.

EXAMPLES

[0356] The following examples illustrate certain embodiments of the present disclosure and are not limiting. Moreover, where specific embodiments are provided, the inventors have contemplated generic application of those specific embodiments. For example, disclosure of an oligonucleotide having a particular motif provides reasonable support for additional oligonucleotides having the same or similar motif. And, for example, where a particular modification appears at a particular position, other modifications at the same position are considered suitable, unless otherwise indicated.

[0357] Synthesis of Oligomeric Compounds

[0358] The oligonucleotides and oligomeric compounds provided herein can be prepared by any of the applicable techniques of organic synthesis. Many such techniques are well known in the art and described in *Compendium of Organic Synthetic Methods*, John Wiley & Sons, New York:

Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade Jr., 1980; Vol. 5, Leroy G. Wade Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., *Advanced Organic Chemistry*, 3rd Edition, John Wiley & Sons, New York, 1985; *Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry*, in 9 Volumes, Barry M. Trost, Editor-in-Chief, Pergamon Press, New York, 1993; *Advanced Organic Chemistry, Part B: Reactions and Synthesis*, 4th Edition: Carey and Sundberg, Kluwer Academic/Plenum Publishers, New York, 2001; *Advanced Organic Chemistry, Reactions, Mechanisms, and Structure*, 2nd Edition, March, McGraw Hill, 1977; Greene, T. W., and Wutz, P. G. M., *Protecting Groups in Organic Synthesis*, 4th Edition, John Wiley & Sons, New York, 1991; and Larock, R. C., *Comprehensive Organic Transformations*, 2nd Edition, John Wiley & Sons, New York, 1999. Protocols for Oligonucleotides and Analogs, Agrawal, Ed., *Humana Press*, 1993, and/or RNA: Scaringe, *Methods*, 2001, 23, 206-217; Gait et al., *Applications of Chemically synthesized RNA in RNA:Protein Interactions*, Smith, Ed., 1998, 1-36; Gallo et al., *Tetrahedron*, 2001, 57, 5707-5713. Additional methods for solid-phase synthesis may be found in Caruthers U.S. Pat. Nos. 4,415,732; 4,458,066; 4,500,707; 4,668,777; 4,973,679; and 5,132,418; and Koster U.S. Pat. Nos. 4,725,677 and Re. 34,069. Additional methods applicable to synthesis of the compounds herein may be found in U.S. Pat. No. 8,993,738 and US 2014/0316121.

Example 1: Modified ss-siRNAs Complementary to the Hexanucleotide Repeat Region of a C9orf72 Transcript

[0359] Modified oligonucleotides complementary to the hexanucleotide repeat region of human C9orf72 sense transcript or to the hexanucleotide repeat region of human C9orf72 antisense transcript are shown in the tables below. The nucleoside at the 5' end of each oligonucleotide and the two nucleosides at the 3' end of each oligonucleotide are not complementary to the target. In tables 1 and 5, the nucleosides at positions 2-19, e.g., the complementary region, of each oligonucleotide are 100% complementary to the target. In tables 2-4 and 6-8, the nucleosides at positions 2-19 of each oligonucleotide contain 1, 2, or 3 mismatches to the target. All of the mismatches, whether they are inside or outside of the complementary region, are underlined.

TABLE 1

ss-siRNAs 100% complementary to
C9orf72 sense transcript at positions 2-19

Isis No.	Sequence (5' to 3')	SEQ ID NO.
742036	P-T _{es} G ₃ G _{mo} C ₃ C _{mo} C ₃ C _{mo} G ₃ G _{mo} C ₃ C _{mo} C ₃ C _{mo} C ₃ G _{m1} C ₃ C _{m2} C ₃ C _{m3} A _{es} A _e	2
742037	P-T _{es} G ₃ G _{mo} G ₃ C _{mo} C ₃ C _{mo} C ₃ G _{mo} G ₃ C _{mo} C ₃ C _{mo} C ₃ G _{m1} G ₃ C _{m2} C ₃ C _{m3} A _{es} A _e	3
742038	P-T _{es} C ₃ C _{mo} G ₃ G _{mo} C ₃ C _{mo} C ₃ C _{mo} G ₃ G _{mo} C ₃ C _{mo} C ₃ C _{m1} G ₃ G _{m1} C ₃ C _{m2} A _{es} A _e	4
742039	P-T _{es} C ₃ C _{mo} C ₃ G _{mo} G ₃ C _{mo} C ₃ C _{mo} C ₃ G _{mo} G ₃ C _{mo} C ₃ C _{m1} C ₃ G _{m1} G ₃ C _{m2} A _{es} A _e	5

TABLE 1-continued

ss-siRNAs 100% complementary to C9orf72 sense transcript at positions 2-19		
Isis		SEQ
No.	Sequence (5' to 3')	ID NO.
742040	P- <u>T</u> _{es} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{ms} C _β C _{ms} G _β G _{ms} <u>A_{es}A_e</u>	6
742041	P- <u>T</u> _{es} G _β C _{mo} C _β C _{mo} C _β G _{mo} G _β C _{mo} C _β C _{mo} C _β G _{mo} G _β C _{ms} C _β C _{ms} C _β G _{ms} <u>A_{es}A_e</u>	7

TABLE 2

ss-siRNAs with a single mismatch to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742042	P- <u>T</u> _{es} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β <u>A</u> _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} <u>A</u> _{es} <u>A</u> _e	8
742043	P- <u>T</u> _{es} C _β G _{mo} G _β C _{mo} C _β C _{mo} C _β <u>A</u> _{mo} G _β C _{mo} C _β C _{mo} C _β G _{ms} G _β C _{ms} C _β C _{ms} <u>A</u> _{es} <u>A</u> _e	9
742044	P- <u>T</u> _{es} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β <u>A</u> _{mo} G _β G _{mo} C _β C _{mo} C _β C _{ms} G _β G _{ms} C _β C _{ms} <u>A</u> _{es} <u>A</u> _e	10
742045	P- <u>T</u> _{es} C _β C _{mo} C _β G _{mo} C _β C _{mo} C _β <u>A</u> _{mo} C _β G _{mo} G _β C _{mo} C _β C _{ms} C _β G _{ms} G _β C _{ms} <u>A</u> _{es} <u>A</u> _e	11
742046	P- <u>T</u> _{es} C _β C _{mo} C _β C _{mo} G _β C _{mo} C _β <u>A</u> _{mo} C _β C _{mo} G _β G _{mo} C _β C _{ms} C _β C _{ms} G _β G _{ms} <u>A</u> _{es} <u>A</u> _e	12
742047	P- <u>T</u> _{es} G _β C _{mo} C _β C _{mo} C _β C _{mo} G _β <u>A</u> _{mo} C _β C _{mo} C _β G _{mo} G _β C _{ms} C _β C _{ms} C _β G _{ms} <u>A</u> _{es} <u>A</u> _e	13

TABLE 3

ss-siRNAs with two mismatches to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742054	P- <u>T</u> _{es} G ₅ G _{mo} C ₅ C _{mo} C ₅ C _{mo} G ₅ <u>A</u> _{no} C ₅ C _{mo} C ₅ C _{mo} <u>A</u> ₅ G _{ms} C ₅ C _{ms} C ₅ C _{ms} <u>A</u> _{es} A _e	14
742055	P- <u>T</u> _{es} C ₅ G _{mo} G ₅ C _{mo} C ₅ C _{mo} C ₅ <u>A</u> _{no} G ₅ C _{mo} C ₅ C _{mo} <u>A</u> ₅ G _{ms} G ₅ C _{ms} C ₅ C _{ms} <u>A</u> _{es} A _e	15
742056	P- <u>T</u> _{es} C ₅ C _{mo} G ₅ G _{mo} C ₅ C _{mo} C ₅ <u>A</u> _{no} G ₅ G _{mo} C ₅ C _{mo} <u>A</u> ₅ G _{ms} G ₅ G _{ms} C ₅ C _{ms} <u>A</u> _{es} A _e	16
742057	P- <u>T</u> _{es} C ₅ C _{mo} C ₅ G _{mo} G ₅ C _{mo} C ₅ <u>A</u> _{no} C ₅ G _{mo} G ₅ C _{mo} <u>A</u> ₅ G _{ms} C ₅ G _{ms} G ₅ C _{ms} <u>A</u> _{es} A _e	17
742058	P- <u>T</u> _{es} C ₅ C _{mo} C ₅ C _{mo} G ₅ G _{mo} C ₅ <u>A</u> _{no} C ₅ C _{mo} G ₅ C _{mo} <u>A</u> ₅ G _{ms} C ₅ G _{ms} G ₅ C _{ms} <u>A</u> _{es} A _e	18
742059	P- <u>T</u> _{es} G ₅ C _{mo} C ₅ C _{mo} C ₅ G _{mo} G ₅ <u>A</u> _{no} C ₅ C _{mo} C ₅ G _{mo} <u>A</u> ₅ G _{ms} C ₅ C _{ms} C ₅ C _{ms} <u>A</u> _{es} A _e	19

TABLE 4

ss-siRNAs with three mismatches to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742048	P- <u>T_{es}</u> G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β <u>A_{mo}A_β</u> A _{no} C _β C _{mo} C _β G _{ms} C _β C _{ms} C _β <u>A_{ms}A_e</u>	20
742049	P- <u>T_{es}</u> C _β G _{mo} G _β C _{mo} C _β C _{mo} C _β <u>A_{mo}A_β</u> A _{no} C _β C _{mo} C _β G _{ms} C _β C _{ms} C _β <u>A_{ms}A_e</u>	21
742050	P- <u>T_{es}</u> C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β <u>A_{mo}A_β</u> A _{no} C _β C _{mo} C _β C _{ms} C _β G _{ms} C _β <u>A_{ms}A_e</u>	22

TABLE 4-continued

ss-siRNAs with three mismatches to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742051	P- <u>T_{es}</u> C _β C _{mo} C _β G _{mo} G _β C _{mo} C _β <u>A_{mo}A_β</u> A _{no} G _β C _{mo} C _β C _{ms} C _β G _{ms} C _β <u>A_{ms}A_e</u>	23
742052	P- <u>T_{es}</u> C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β <u>A_{mo}A_β</u> A _{no} G _β G _{mo} C _β C _{ms} C _β C _{ms} C _β <u>A_{ms}A_e</u>	24
742053	P- <u>T_{es}</u> G _β C _{mo} C _β C _{mo} C _β G _{mo} G _β <u>A_{mo}A_β</u> A _{no} C _β G _{mo} G _β C _{ms} C _β C _{ms} C _β <u>A_{ms}A_e</u>	25

TABLE 5

ss-siRNAs 100% complementary to C9orf72 antisense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742060	P- <u>T_{es}</u> G _β G _{mo} G _β G _{mo} C _β C _{mo} G _β G _{mo} G _β C _{mo} C _β G _{ms} G _β G _{ms} C _β <u>A_{ms}A_e</u>	26
742061	P- <u>T_{es}</u> C _β G _{mo} G _β G _{mo} G _β C _{mo} C _β G _{mo} G _β C _{mo} C _β G _{ms} G _β G _{ms} C _β <u>A_{ms}A_e</u>	27
742062	P- <u>T_{es}</u> C _β C _{mo} G _β G _{mo} G _β G _{mo} C _β C _{mo} G _β G _{mo} C _β C _{ms} G _β G _{ms} G _β <u>A_{ms}A_e</u>	28
742063	P- <u>T_{es}</u> G _β C _{mo} C _β G _{mo} G _β G _{mo} G _β C _{mo} C _β G _{mo} G _β C _{ms} C _β G _{ms} G _β <u>A_{ms}A_e</u>	29
742064	P- <u>T_{es}</u> G _β G _{mo} C _β C _{mo} G _β G _{mo} G _β C _{mo} C _β G _{mo} G _β C _{ms} C _β G _{ms} G _β <u>A_{ms}A_e</u>	30
742065	P- <u>T_{es}</u> G _β G _{mo} C _β C _{mo} C _β G _{mo} G _β G _{mo} C _β C _{mo} C _β G _{ms} C _β <u>A_{ms}A_e</u>	31

TABLE 6

ss-siRNAs with a single mismatch to C9orf72 antisense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742066	P- <u>T_{es}</u> G _β G _{mo} G _β G _{mo} C _β C _{mo} G _β A _{no} G _β G _{mo} C _β C _{mo} G _β G _{ms} G _β C _{ms} C _β <u>A_{ms}A_e</u>	32
742067	P- <u>T_{es}</u> C _β G _{mo} G _β G _{mo} G _β C _{mo} C _β A _{no} G _β G _{mo} G _β C _{ms} G _β G _{ms} G _β C _{ms} C _β <u>A_{ms}A_e</u>	33
742068	P- <u>T_{es}</u> C _β C _{mo} G _β G _{mo} G _β G _{mo} C _β A _{no} G _β G _{mo} C _β C _{ms} G _β G _{ms} G _β <u>A_{ms}A_e</u>	34
742069	P- <u>T_{es}</u> G _β C _{mo} C _β G _{mo} G _β G _{mo} C _β A _{no} C _β G _{mo} G _β C _{ms} C _β G _{ms} G _β <u>A_{ms}A_e</u>	35
742070	P- <u>T_{es}</u> G _β G _{mo} C _β C _{mo} G _β G _{mo} C _β A _{no} C _β C _{mo} G _β G _{ms} C _β C _{ms} G _β G _{ms} <u>A_{ms}A_e</u>	36
742071	P- <u>T_{es}</u> G _β G _{mo} G _β C _{mo} C _β G _{mo} G _β A _{no} G _β C _{mo} C _β G _{mo} G _β C _{ms} C _β G _{ms} <u>A_{ms}A_e</u>	37

TABLE 7

ss-siRNAs with two mismatches to C9orf72 antisense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742078	P- <u>T_{es}</u> G _β G _{mo} G _β G _{mo} C _β C _{mo} G _β A _{no} G _β C _{mo} C _β G _{ms} G _β C _{ms} C _β <u>A_{ms}A_e</u>	38
742079	P- <u>T_{es}</u> C _β G _{mo} G _β G _{mo} G _β C _{mo} C _β A _{no} G _β G _{mo} C _β A _{ms} G _β G _{ms} G _β C _{ms} C _β <u>A_{ms}A_e</u>	39
742080	P- <u>T_{es}</u> C _β C _{mo} G _β G _{mo} G _β G _{mo} C _β A _{no} G _β G _{mo} C _β A _{ms} C _{ms} G _β G _{ms} G _β <u>A_{ms}A_e</u>	40
742081	P- <u>T_{es}</u> G _β C _{mo} C _β G _{mo} G _β G _{mo} C _β A _{no} C _β G _{mo} G _β C _{ms} C _β G _{ms} G _β <u>A_{ms}A_e</u>	41
742082	P- <u>T_{es}</u> G _β G _{mo} C _β C _{mo} G _β G _{mo} G _β A _{no} C _β C _{mo} G _β A _{ms} C _{ms} C _β G _{ms} G _β <u>A_{ms}A_e</u>	42
742083	P- <u>T_{es}</u> G _β G _{mo} G _β C _{mo} C _β G _{mo} G _β A _{no} G _β C _{mo} C _β G _{mo} G _β C _{ms} C _β G _{ms} <u>A_{ms}A_e</u>	43

TABLE 8

ss-siRNAs with three mismatches to C9orf72 antisense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
742072	P-T _{es} G _β G _{mo} G _β G _{mo} C _β C _{mo} G _β A _{mo} A _β A _{mo} C _β C _{mo} G _β G _{ms} G _β G _{ms} C _β C _{ms} A _{es} A _e	44
742073	P-T _{es} C _β G _{mo} G _β G _{mo} G _β C _{mo} C _β A _{mo} A _β A _{mo} G _β C _{mo} C _β G _{ms} G _β G _{ms} G _β C _{ms} A _{es} A _e	45
742074	P-T _{es} C _β C _{mo} G _β G _{mo} G _β G _{mo} C _β A _{mo} A _β A _{mo} G _β C _{mo} C _β C _{ms} G _β G _{ms} G _β C _{ms} A _{es} A _e	46
742075	P-T _{es} G _β C _{mo} C _β G _{mo} G _β G _{mo} G _β A _{mo} A _β A _{mo} G _β C _{mo} G _β C _{ms} C _β G _{ms} G _β C _{ms} A _{es} A _e	47
742076	P-T _{es} G _β G _{mo} C _β C _{mo} G _β G _{mo} G _β A _{mo} A _β A _{mo} G _β C _{mo} G _β G _{ms} C _β C _{ms} G _β C _{ms} A _{es} A _e	48
742077	P-T _{es} G _β G _{mo} G _β C _{mo} C _β C _{mo} G _β A _{mo} A _β A _{mo} C _β C _{mo} G _β G _{ms} G _β C _{ms} C _β C _{ms} A _{es} A _e	49

Subscripts: "s" indicates a phosphorothioate internucleoside linkage; "o" indicates an unmodified, phosphate internucleoside linkage; "f" indicates a 2'-fluoro modified nucleoside; "m" indicates a 2'-O-methyl modified nucleoside; and "e" indicates a 2'-O-methoxyethyl (MOE) modified nucleoside. "p" at the 5'-end indicates a terminal phosphate group at the 5'-position.

Example 2: Inhibitory Effects of Modified ss-siRNAs on C9orf72 Foci In Vitro

[0360] Modified oligonucleotides described in Example 1 were tested for their effects on C9orf72 foci in ALS/FTD patient fibroblast cell lines. The fibroblast cells were plated at a density of 10,000 cells per well into Lab-Tek 8-well chambered cover glass slides. One day later, Isis No. 742048, 742054, 742072, or 742078 was added, or a control. The "CM" negative control is an oligonucleotide with a sequence that is not complementary to a C9orf72 transcript. The "siRNA" positive control is a siRNA that is complementary to a C9orf72 transcript. Two days after oligonucleotide treatment, cells were fixed with 4% formaldehyde in 1xPBS and permeabilized in 70% ethanol at 4° C. overnight. Cells were washed with Wash Buffer (10% formamide in 2xSSC) for 5 minutes, and then incubated with pre-hybridization buffer (40% formamide in 2xSSC) at 60° C. for 20 minutes. A (CCCCGG)₄-Cy3 DNA probe or a (GGGGCC)_{3,3}-Cy3 probe in Hybridization Buffer (100 mg/mL dextran sulfate and 40% formamide in 2xSSC) was added. The slide was placed in a humidified chamber and incubated in the dark at 37° C. overnight. The next day, cells were washed twice with wash buffer at 37° C., then stained with mounting media and DAPI (Vector Labs, H-1500).

[0361] Cells were imaged at 60x magnification using a Widefield Deltavision microscope. Images were processed by blind deconvolution with AutoQuant X3 and ImageJ. For quantification, at least 20 pictures were taken from randomly chosen microscopic fields, containing 100-300 cells for each treatment. The average percentage of the total number of cells containing RNA foci and the number of foci per 100 cells was calculated for each oligonucleotide treatment. The results, shown in FIGS. 1A-D, indicate that the modified

oligonucleotides targeting the C9orf72 sense transcript decreased the number of C9orf72 sense foci, and the modified oligonucleotides targeting the C9orf72 antisense transcript decreased the number of C9orf72 antisense foci. Furthermore, most of the modified oligonucleotides decreased C9orf72 foci to a greater extent than the "siRNA" positive control.

Example 3: Inhibitory Effect of Modified ss-siRNAs on C9orf72 Expression In Vivo

[0362] The modified ss-siRNAs targeting the hexanucleotide repeat region of C9orf72, listed below, are evaluated for their ability to inhibit C9orf72 expression in mice. Transgenic mice are injected subcutaneously with one of the modified ss-siRNAs, listed below, or with saline as a control. Each treatment group will include 4 animals. Each mouse is treated with one of the following dosing regimens: (1) Dose of 10 mg/kg administered as a single dose of 10 mg/kg; (2) Dose of 25 mg/kg administered as a single dose of 25 mg/kg; (3) Dose of 100 mg/kg administered as a series of doses of 25 mg/kg given twice a day for two days (for a total of 100 mg/kg); (4) Dose of 300 mg/kg administered as a series of doses of 25 mg/kg given twice a day for six days (for a total of 300 mg/kg).

[0363] Seventy-two hours after the administration of the last dose, the mice are sacrificed and tissue is collected for analysis. C9orf72 mRNA levels in liver are determined using real-time PCR and according to standard protocols and C9orf72 mRNA levels are determined relative to total RNA (using Cyclophilin), prior to normalization to PBS-treated control. C9orf72 protein levels are measured using standard Western blot analysis (immunoblot analysis). C9orf72 foci were also measured, as described in Example 2, in sections of the collected tissues.

TABLE 9

ss-siRNAs 100% complementary to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748438	PV-T _{es} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	2
748439	PV-T _{es} C _β G _{mo} G _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	3
748440	PV-T _{es} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	4

TABLE 9-continued

ss-siRNAs 100% complementary to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748441	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{ms} C _{js} G _{ms} G _{js} C _{ms} <u>A_{es}A_e</u>	5
748442	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} G _{js} C _{mo} C _{js} C _{ms} C _{js} C _{ms} G _{js} G _{ms} <u>A_{es}A_e</u>	6
748443	PV-T _{es} G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} G _{js} C _{ms} C _{js} C _{ms} G _{ms} <u>A_{es}A_e</u>	7

TABLE 10

ss-siRNAs with a single mismatch to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748444	PV-T _{es} G _{js} G _{mo} C _{js} C _{mo} C _{js} C _{mo} G _{js} <u>A_{mo}</u> C _{js} C _{mo} C _{js} C _{mo} G _{js} G _{ms} C _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	8
748445	PV-T _{es} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{ms} G _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	9
748446	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> G _{js} G _{mo} C _{js} C _{mo} C _{js} C _{ms} G _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	10
748447	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} <u>A_{mo}</u> C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{ms} C _{js} G _{ms} G _{js} C _{ms} <u>A_{es}A_e</u>	11
748448	PV-T _{es} C _{js} C _{mo} C _{js} C _{mo} G _{js} G _{mo} C _{js} <u>A_{mo}</u> C _{js} C _{mo} G _{js} C _{ms} C _{js} C _{ms} G _{js} G _{ms} <u>A_{es}A_e</u>	12
748449	PV-T _{es} G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{mo} G _{js} <u>A_{mo}</u> C _{js} C _{mo} C _{js} C _{mo} G _{js} C _{ms} C _{js} C _{ms} G _{ms} <u>A_{es}A_e</u>	13

TABLE 11

ss-siRNAs with two mismatches to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748456	PV-T _{es} G _{js} G _{mo} C _{js} C _{mo} C _{js} C _{mo} G _{js} <u>A_{mo}</u> C _{js} C _{mo} C _{js} C _{mo} <u>A_{js}</u> G _{ms} C _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	14
748457	PV-T _{es} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> G _{js} C _{mo} C _{js} C _{mo} <u>A_{js}</u> G _{ms} G _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	15
748458	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} <u>A_{mo}</u> C _{js} G _{mo} G _{js} C _{mo} <u>A_{js}</u> C _{ms} C _{js} G _{ms} G _{js} C _{ms} <u>A_{es}A_e</u>	17
748459	PV-T _{es} C _{js} C _{mo} C _{js} C _{mo} G _{js} G _{mo} C _{js} <u>A_{mo}</u> C _{js} C _{mo} G _{js} C _{mo} <u>A_{js}</u> C _{ms} C _{js} C _{ms} G _{ms} <u>A_{es}A_e</u>	18
748460	PV-T _{es} G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{mo} G _{js} <u>A_{mo}</u> C _{js} C _{mo} C _{js} C _{mo} <u>A_{js}</u> C _{ms} C _{js} C _{ms} G _{ms} <u>A_{es}A_e</u>	19
n/a	PV-T _{es} C _{js} C _{mo} G _{js} G _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> G _{js} G _{mo} C _{js} C _{mo} <u>A_{js}</u> C _{ms} G _{js} G _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	19

TABLE 12

ss-siRNAs with three mismatches to C9orf72 sense transcript at positions 2-19		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748450	PV-T _{es} G _{js} G _{mo} C _{js} C _{mo} C _{js} C _{mo} G _{js} <u>A_{mo}</u> <u>A_{js}</u> C _{js} C _{mo} G _{js} G _{ms} C _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	20
748451	PV-T _{es} C _{js} G _{mo} G _{js} C _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> <u>A_{js}</u> C _{js} C _{mo} C _{js} G _{ms} G _{js} C _{ms} C _{js} C _{ms} <u>A_{es}A_e</u>	21
748452	PV-T _{es} C _{js} C _{mo} G _{js} G _{mo} C _{js} C _{mo} C _{js} <u>A_{mo}</u> <u>A_{js}</u> C _{js} C _{mo} C _{js} C _{ms} G _{js} G _{ms} C _{ms} <u>A_{es}A_e</u>	22
748453	PV-T _{es} C _{js} C _{mo} C _{js} G _{mo} G _{js} C _{mo} C _{js} <u>A_{mo}</u> <u>A_{js}</u> G _{js} C _{mo} C _{js} C _{ms} C _{js} G _{ms} G _{js} C _{ms} <u>A_{es}A_e</u>	23
748454	PV-T _{es} C _{js} C _{mo} C _{js} C _{mo} G _{js} G _{mo} C _{js} <u>A_{mo}</u> <u>A_{js}</u> G _{js} C _{mo} C _{js} C _{ms} C _{js} C _{ms} G _{js} G _{ms} <u>A_{es}A_e</u>	24
748455	PV-T _{es} G _{js} C _{mo} C _{js} C _{mo} C _{js} G _{mo} G _{js} <u>A_{mo}</u> <u>A_{js}</u> C _{js} C _{mo} G _{js} C _{ms} C _{js} C _{ms} G _{ms} <u>A_{es}A_e</u>	25

TABLE 13

<u>ss-siRNAs 100% complementary to C9orf72 antisense transcript at positions 2-19</u>		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748461	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{ms} G ₃ G _{ms} C ₃ C _{ms} <u>A_{es}A_e</u>	26
748462	PV- <u>T</u> _{es} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{ms} G ₃ G _{ms} C _{ms} <u>A_{es}A_e</u>	27
748463	PV- <u>T</u> _{es} C ₃ C _{mo} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	28
748464	PV- <u>T</u> _{es} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	29
748465	PV- <u>T</u> _{es} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{ms} C ₃ C _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	30
748466	PV- <u>T</u> _{es} G ₃ G _{mo} C ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{ms} G ₃ C _{ms} C ₃ G _{ms} <u>A_{es}A_e</u>	31

TABLE 14

<u>ss-siRNAs with a single mismatch to C9orf72 antisense transcript at positions 2-19</u>		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748467	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ <u>A_{mo}</u> G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{ms} G ₃ G _{ms} C ₃ C _{ms} <u>A_{es}A_e</u>	32
748468	PV- <u>T</u> _{es} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{ms} G ₃ G _{ms} C _{ms} <u>A_{es}A_e</u>	33
748469	PV- <u>T</u> _{es} C ₃ C _{mo} G ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	34
748470	PV- <u>T</u> _{es} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	35
748471	PV- <u>T</u> _{es} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ <u>A_{mo}</u> C ₃ C _{mo} G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	36
748472	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ <u>A_{mo}</u> G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{ms} G ₃ C _{ms} C ₃ G _{ms} <u>A_{es}A_e</u>	37

TABLE 15

<u>ss-siRNAs with two mismatches to C9orf72 antisense transcript at positions 2-19</u>		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748479	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ <u>A_{mo}</u> G ₃ G _{mo} C ₃ C _{mo} <u>A₃</u> G ₃ G _{ms} G ₃ G _{ms} C ₃ C _{ms} <u>A_{es}A_e</u>	38
748480	PV- <u>T</u> _{es} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{mo} <u>A₃</u> G ₃ G _{ms} G ₃ G _{ms} C _{ms} <u>A_{es}A_e</u>	39
748481	PV- <u>T</u> _{es} C ₃ C _{mo} G ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} <u>A₃</u> G ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	40
748482	PV- <u>T</u> _{es} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} <u>A₃</u> G ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	41
748483	PV- <u>T</u> _{es} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ <u>A_{mo}</u> C ₃ C _{mo} G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	42
748484	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ <u>A_{mo}</u> G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{ms} G ₃ C _{ms} C ₃ G _{ms} <u>A_{es}A_e</u>	43

TABLE 16

<u>ss-siRNAs with three mismatches to C9orf72 antisense transcript at positions 2-19</u>		
Isis No.	Sequence (5' to 3')	SEQ ID NO.
748473	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ G _{mo} C ₃ C _{mo} G ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> C ₃ C _{mo} G ₃ G _{ms} G ₃ G _{ms} C ₃ C _{ms} <u>A_{es}A_e</u>	44
748474	PV- <u>T</u> _{es} C ₃ G _{mo} G ₃ G _{mo} G ₃ C _{mo} C ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{ms} G ₃ G _{ms} C _{ms} <u>A_{es}A_e</u>	45
748475	PV- <u>T</u> _{es} C ₃ C _{mo} G ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	46
748476	PV- <u>T</u> _{es} G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{mo} C ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	47
748477	PV- <u>T</u> _{es} G ₃ G _{mo} C ₃ C _{mo} G ₃ G _{mo} G ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> G ₃ G _{mo} G ₃ C _{ms} C ₃ G _{ms} G ₃ G _{ms} <u>A_{es}A_e</u>	48
748478	PV- <u>T</u> _{es} G ₃ G _{mo} G ₃ C _{mo} C ₃ G _{mo} G ₃ <u>A_{mo}</u> <u>A₃</u> <u>A_{mo}</u> G ₃ C _{mo} C ₃ G _{mo} G ₃ G _{ms} G ₃ C _{ms} C ₃ G _{ms} <u>A_{es}A_e</u>	49

[0364] Subscripts: “s” indicates a phosphorothioate internucleoside linkage; “o” indicates an unmodified, phosphate internucleoside linkage; “f” indicates a 2'-fluoro modified nucleoside; “in” indicates a 2'-O-methyl modified nucleoside; and “e” indicates a 2'-O-methoxyethyl (MOE) modified nucleoside. “Pv” at the 5'-end indicates a 5'-(E)-vinylphosphonate group, (PO(OH)₂(CH=CH—).

Example 4: Inhibitory Effects of Modified ss-siRNAs Complementary to C9orf72 Sense Transcript on C9orf72 Sense Foci In Vitro

[0365] Modified oligonucleotides described in Example 1 were tested for their effects on C9orf72 foci in ALS/FTD patient fibroblast cell lines.
qPCR Analysis

[0366] The fibroblast cells were plated at a density of 80,000 cells per well of a 6-well plaque 48 hours before transfection with a cationic lipid for qPCR analysis. Cells were typically harvested 2 days after transfection. Modified oligonucleotides (listed in Table 18) or controls (described in Table 17) were added.

TABLE 17

Control oligonucleotides			
Identifier	Sequence (5'-3')	Target description	SEQ ID NO
cs1	Pv- T _{es} C _{fs} U _{mo} G _{fs} C _{mo} U _{fs} G _{mo} C _{fs} A _{mo} A _{fs} A _{mo} U _{fs} G _{mo} C _{fs} U _{ms} G _{fs} C _{ms} U _{fs} G _{ms} A _{es} A _e	CAG	50
cs2	Pv- N _{es} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{mo} N _{fs} N _{es} N _e	Unrelated target	51
cs3	Pv- T _{es} A _{fs} A _{mo} C _{fs} U _{mo} U _{fs} C _{mo} A _{fs} G _{mo} G _{fs} G _{mo} U _{fs} C _{mo} A _{fs} C _{ms} C _{fs} U _{ms} U _{fs} C _{ms} A _{es} A _e	EGFP	52
Duplex RNA (antisense strand, 5'-3')			
R3	CGGCCCCGAAACCGCCCCdTdT	Repeat	53
C1	GCUAUACCAGCGUCGUCAUdTdT	Control-Repeat	54

Subscripts: “s” indicates a phosphorothioate internucleoside linkage; “o” indicates an unmodified, phosphate internucleoside linkage; “f” indicates a 2'-fluoro modified nucleoside; “m” indicates a 2'-O-methyl modified nucleoside; and “e” indicates a 2'-O-methoxyethyl (MOE) modified nucleoside. “Pv” at the 5'-end indicates a 5'-(E)-vinylphosphonate group, (PO(OH)₂(CH=CH—). “N” indicates an undisclosed base. Control “cs2” is not complementary to human C9orf72 and targets an unrelated gene. All of the mismatches, whether they are inside or outside of the complementary region, are underlined, “d” in the duplex RNA controls indicates a 2'-deoxynucleoside.

[0367] C9orf72 expression was analyzed by quantitative PCR on a 7500 real-time PCR system (Applied Biosystems) using iTaq SYBR Green Supermix (Bio-Rad). Data was normalized relative to levels of GAPDH mRNA. Primers specific for C9orf72 mRNA are as follows: all three variants

(Forward (SEQ ID NO: 55)
5'-AGAAGGCACAGAGAGAATGGAA-3';
Reverse (SEQ ID NO: 56)
5'-TCATCATCATTGAGTACTGTATCAGC-3';
C9orf72 intron 1
(Forward (SEQ ID NO: 57)
5'-ACGCCTGCACAATTTAGCCCAA-3';

-continued

Reverse (SEQ ID NO: 58)
5'-CAAGTCTGTGTCATCTCGGAGCTG-3';
and
GAPDH
Forward (SEQ ID NO: 59)
5'-GTCATCAATGGAAATCCCATCAC-3';
Reverse (SEQ ID NO: 60)
5'-TTCTCCATGGTGGTGAAGAC-3'.

RNA RISH and Imaging

[0368] RNA fluorescent in situ hybridization (FISH) was performed following a Biosearch protocol with minor modification. Fibroblast cells were plated at a density of 10,000/well into Lab-Tek 8-well chambered cover glass slides. After one day, siRNA/lipid complex were added at 50 nM final concentration. 48 hours after transfection, cells were fixed

with 4% formaldehyde in 1×PBS and permeabilized in 70% ethanol at 4° C. overnight. Cells were washed with Wash Buffer (10% formamide in 2×SSC) for 5 minutes, and then incubated with pre-hybridization buffer (40% formamide in 2×SSC) at 60° C. for 20 minutes. A (CCCCGG)₄-Cy3 DNA probe or a (GGGGCC)_{3,3}-Cy3 probe in Hybridization Buffer (100 mg/mL dextran sulfate and 40% formamide in 2×SSC) was added. The slide was placed in a humidified chamber and incubated in the dark at 37° C. overnight. The next day, cells were washed twice with wash buffer at 37° C., then stained with mounting media and DAPI (Vector Labs, H-1500).

[0369] Cells were imaged at 60× magnification using a Widefield Deltavision microscope. Images were processed by blind deconvolution with AutoQuant X3. Visualization of RNA foci were made using ImageJ. For quantification, at least 20 pictures were taken from randomly chosen micro-

scopic fields, containing 100-300 cells for each treatment. Counting foci was performed by different investigators. All data were generated by at least three independent experiments.

[0370] The results, provided in Table 18 and FIGS. 2A-B, indicate that the modified oligonucleotides targeting the C9orf72 sense transcript decreased the percent total cells with C9orf72 sense foci and the number of C9orf72 sense foci per 100 cells as compared to controls.

TABLE 18

ss-siRNAs complementary to C9orf72 sense transcript reduce sense foci in ALS/FTD patient fibroblast cells			
Identifier	# of Mismatches or control description	% Total cells with foci	# Foci per 100 cells
742036	0	1.1	1.1
742037	0	1.8	1.5
742038	0	6.5	7.1
742039	0	0.8	1.9
742040	0	2.0	2.0
742041	0	0.8	2.5
742042	1	12	16
742048	3	7.5	9.6
742049	3	15	30
742050	3	13	14
742051	3	12	12
742054	2	13	19
cs1	Control - CAG repeat	41	112
cs2	Control - Unrelated target	34	75
cs3	Control - EGFP	42	94
R3	Control - Repeat	13	28
C1	Control - No target	46	120

Example 5: Inhibitory Effects of Modified
Ss-siRNAs Complementary to C9orf72 Antisense
Transcript on C9orf72 Antisense Foci In Vitro

[0371] Modified oligonucleotides described in Example 1 were tested for their effects on C9orf72 antisense foci in ALS/FTD patient fibroblast cell lines. qPCR, RNA FISH, and imaging were conducted as described in Example 4. Controls are described in Example 4. The results, provided in Table 19 and FIGS. 3A-B, indicate that the modified oligonucleotides targeting the C9orf72 antisense transcript decreased the percent total cells with C9orf72 antisense foci and the number of C9orf72 antisense foci per 100 cells as compared to controls.

TABLE 19

ss-siRNAs complementary to C9orf72 antisense transcript reduce antisense foci in ALS/FTD patient fibroblast cells			
Identifier	# of Mismatches or control description	% Total cells with foci	# Foci per 100 cells
742060	0	16	33
742061	0	19	26
742066	1	11	16
742072	3	17	34
742073	3	33	65
742074	3	34	88
742075	3	28	65
742078	2	15	25
cs2	Control - Unrelated target	53	207
cs3	Control - EGFP	51	181

Example 6: Effects of Modified ss-siRNA Lacking
a 5'-Phosphate on C9orf72 Foci In Vitro

[0372] Isis 918924 and 918925, each lacking a 5'-phosphate, and complementary to the hexanucleotide repeat region of human C9orf72 sense transcript were tested in ALS/FTD patient fibroblast cell lines. qPCR, RNA FISH, and imaging were conducted as described in Example 4. Control "cs3" is described in Example 4. Isis 918924 and 918925 are analogs of 742036 and 742048 (respectively). Isis 918924 and 918925 are described in Table 20.

[0373] Isis 918924 and 918925 were tested in ALS/FTD patient fibroblast cell lines to determine whether multiple RNAi mechanisms contribute to blocking C9orf72 foci. A 5'-phosphate is required for an ss-siRNA containing a 5'-terminal methoxyethyl base to function through an RNA mechanism. Therefore, if Isis 918924 and 918925 are effective in reducing foci, then they are working through a non-RNAi mechanism. The results, provided in Table 20 and FIG. 4A indicate that Isis 918924 was as potent as analogous Isis 742036, demonstrating that GGGGCC ss-siRNAs can act through a non-RNAi mechanism. Table 20 and FIG. 4B indicate that Isis 918925 was less active than analogous Isis 742048. Isis 918925 may be less active because when mismatches are present, they destabilize interactions with the target. This destabilization may prevent efficient recognition in the absences of assistance by RNAi factors. The ability of a mismatched single strand to use RNAi factors like argonaute may be indispensable for maximal activity.

TABLE 20

Effect of ss-siRNAs lacking a 5'-phosphate on C9orf72 sense foci					
Identfier	Sequence (5'-3')	# of Mismatches or control description	% Total cells with foci	# Foci per 100 cells	SEQ ID NO
742036	Pv- T _{es} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	0	4.8	6.5	2
742048	Pv- T _{es} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β ~~A_{es}A_{es}A_{es}~~ C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	3	6.1	9.1	20
918924	T _{es} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{mo} C _β C _{mo} C _β C _{mo} G _β G _{ms} C _β C _{ms} C _β C _{ms} A _{es} A _e	0	4.1	5.8	2

TABLE 20-continued

Effect of ss-siRNAs lacking a 5'-phosphate on C9orf72 sense foci				
Identifier	Sequence (5'-3')	# of Mismatches or control description	% Total cells with foci	# Foci per 100 cells
918925	<u>T_{es}G_{js}G_{mo}C_{js}C_{mo}C_{js}C_{mo}G_{js}A_{mo}A_{js}A_{mo}C_{js}C_{mo}G_{js}G_{ms}</u> <u>C_{js}C_{ms}C_{js}C_{ms}A_{es}A_e</u>	3	30	58
cs3	Pv- <u>T_{es}A_{js}A_{mo}C_{js}U_{mo}U_{js}C_{mo}A_{js}G_{mo}G_{js}G_{mo}U_{js}C_{mo}A_{js}G_{ms}</u> <u>C_{js}U_{ms}U_{js}G_{ms}A_{es}A_e</u>	Control-EGFP	42	106
				52

Subscripts: “s” indicates a phosphorothioate internucleoside linkage; “o” indicates an unmodified, phosphate internucleoside linkage; “f” indicates a 2'-fluoro modified nucleoside; “in” indicates a 2'-O-methyl modified nucleoside; and “e” indicates a 2'-O-methoxyethyl (MOE) modified nucleoside.

“Pv” at the 5'-end indicates a 5'-(E)-vinylphosphonate group, (PO(OH)₂(CH=CH—)). All of the mismatches, whether they are inside or outside of the complementary region, are underlined.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 60

<210> SEQ ID NO 1

<211> LENGTH: 30001

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

caaagaaaag ggggaggttt tgttaaaaaa gagaaatggt acatagtgtt ctttgagaaa      60
attcattggc actattaagg atctgaggag ctggtgagtt tcaactgggt agtgatgggt      120
gtagataaaa ttagagctgc agcaggtcat tttagcaact attagataaa actggtctca      180
ggtcacaacg ggcagttgca gcagctggac ttggagagaa ttacactgtg ggagcagtg      240
catttgcctt aagtgttttt ctacccccta cccccactat tttagttggg tataaaaaga      300
atgaccaaat ttgtatgatc aactttcaca aagcatagaa cagtaggaaa aggggtctgt      360
tctgcagaag gtgtagacgt tgagagccat tttgtgtatt tattcctccc tttcttctc      420
gggtgaatgat taaaacgttc tgtgtgattt ttagtgatga aaaagattaa atgctactca      480
ctgtagtaag tgccatctca cacttgcaga tcaaaaggca cacagtttaa aaaacctttg      540
tttttttaca catctgagtg gtgtaaatgc tactcatctg tagtaagtgg aatctataca      600
cctgcagacc aaaagacgca aggtttcaaa aatctttgtg ttttttacac atcaaacaga      660
atggtacgtt tttcaaaagt taaaaaaaaa caactcatcc acatattgca actagcaaaa      720
atgacattcc ccagtgtgaa aatcatgctt gagagaattc ttacatgtaa aggcaaaatt      780
gcgatgactt tgcaggggac cgtgggattc ccgcccgcag tgcggagct gtccectacc      840
agggtttgca gtggagtttt gaatgcactt aacagtgtct tacggtaaaa acaaaatttc      900
atccaccaat tatgtgttta gcgccactg cctaccaagc acaaacaaaa ccattcaaaa      960
ccacgaaatc gtcttcactt totccagatc cagcagcctc ccctattaag gttcgcacac     1020
gctattgcgc caacgtctct ccagagcggg tcttaagata aaagaacagg acaagttgcc     1080
ccgccccatt tcgctagcct cgtgagaaaa cgtcatcgca catagaaaac agacagacgt     1140
aacctacggt gtcccgttag gaaagagagg tgcgtcaaac agcgacaagt tccgcccacg     1200
taaaagatga cgcttggtgt gtcagccgtc cctgctgccc gggtgtctct cttttggggg     1260

```

-continued

cggggtctag	caagagcagg	tgtgggttta	ggaggtgtgt	gtttttgttt	ttcccacct	1320
ctctccccac	tacttgctct	cacagtactc	gctgaggggtg	aacaagaaaa	gacctgataa	1380
agattaacca	gaagaaaaa	aggagggaaa	caaccgcagc	ctgtagcaag	ctctggaact	1440
caggagtcgc	gcgctagggg	ccggggcccg	ggccggggcg	tggtcggggc	gggcccgggg	1500
gcgggcccgg	ggcggggctg	cggttgcggt	gcctgcgccc	gcggcggcgg	aggcgcaggc	1560
ggtggcgagt	gggtgagtga	ggaggcggca	tccctggcgg	tggtctgttg	gggttcggct	1620
gccgggaaga	ggcgcgggta	gaagcggggg	ctctcctcag	agctcgacgc	atttttactt	1680
tccctctcat	ttctctgacc	gaagctgggt	gtcgggcttt	cgctctagc	gactggtgga	1740
attgcctgca	tccgggcccc	gggcttcccc	gcggcggcgg	cggcggcggc	ggcgcaggga	1800
caagggatgg	ggatctggcc	tcttcttgcc	tttcccgccc	tcagtaccgc	agctgtctcc	1860
ttcccgggga	cccgcctgga	gcgctgccgc	tcggggctcg	agaaaaggga	gcctcgggta	1920
ctgagaggcc	tcgcctgggg	gaaggccgga	gggtgggcgg	cgcgcggttt	ctgcggacca	1980
agtcgggggt	cgctaggaac	ccgagacggt	ccctgccggc	gaggagatca	tcggggatga	2040
gatgggggtg	tggagacgcc	tcacacaatt	cagcccaagc	ttctagagag	tggtgatgac	2100
ttgcatatga	gggcagcaat	gcaagtgggt	gtgctcccca	ttctgtggga	catgacctgg	2160
ttgcttcaca	gctccgagat	gacacagact	tgcttaaagg	aagtgactat	tgtgacttgg	2220
gcatcacttg	actgatggta	atcagttgtc	taaagaagtg	cacagattac	atgtccgtgt	2280
gctcattggg	tctatctggc	cgcggtgaac	accaccaggc	tttgtattca	gaaacaggag	2340
ggaggtcctg	cactttccca	ggaggggtgg	ccctttcaga	tgcaatcgag	attgttaggc	2400
tctgggagag	tagttgcctg	gttgtggcag	ttggtaaatt	tctattcaaa	cagttgccat	2460
gcaccagttg	ttcacacaaa	gggtacgtaa	tctgtctggc	attacttcta	cttttgtaca	2520
aaggatcaaa	aaaaaaaaag	atactgttaa	gatatgattt	ttctcagact	ttgggaaact	2580
tttaacataa	tctgtgaata	tcacagaaac	aagactatca	tataggggat	attaataacc	2640
tggagtcaga	atacttgaaa	tacggtgtca	tttgacacgg	gcattgttgt	caccacctct	2700
gccaaaggct	gccactttag	gaaaaccctg	aatcagttgg	aaactgctac	atgctgatat	2760
tacatctgaa	acaagaacga	gagtaattac	cacattccag	attgttccct	aagccagcat	2820
ttacctgtct	caggaaaaaa	ttacaagcac	cttatgaagt	tgataaaata	ttttgtttgg	2880
ctatgttggc	actccacaat	ttgctttcag	agaaacaaag	taaaccaagg	aggacttctg	2940
tttttcaagt	ctgccctcgg	gttctattct	acgttaatta	gatagttccc	aggaggacta	3000
ggttagccta	cctattgtct	gagaaaactg	gaactgtgag	aaatggccag	atagtatat	3060
gaacttcacc	ttccagtctt	ccctgatgtt	gaagattgag	aaagtgttgt	gaactttctg	3120
gtactgtaaa	cagttcactg	tccttgaagt	ggtcctgggc	agctcctggt	gtggaaagtg	3180
gacggtttag	gatectgctt	ctctttgggc	tgaggagaaa	taaacagcat	ggttacaagt	3240
attgagagcc	aggttgagga	aggtggctta	cacctgtaat	gccagagctt	tgaggaggcg	3300
aggcaagagg	atcacttgaa	gccaggagtt	caagctcaac	ctgggcaacg	tagacctgtt	3360
ctctacaaaa	aattaaaaac	ttagccgggc	gtggtgatgt	gcacctgtag	tcctagctac	3420
ttgggaggct	gaggcaggag	ggtcatttga	gcccgaagag	ttgaagttac	cgagagctat	3480
gatcctgcc	gtgcattoca	gcctggatga	caaacagaga	ccctgtctct	aaaaaacaag	3540

-continued

aagtgagggc	tttatgattg	tagaattttc	actacaatag	cagtggacca	accacctttc	3600
taaataccaa	tcaggggaaga	gatggttgat	tttttaacag	acgttttaaag	aaaaagcaaa	3660
acctcaaaact	tagcactcta	ctaacagttt	tagcagatgt	taattaatgt	aatcatgtct	3720
gcatgtatgg	gattattttc	agaaagtgt	ttgggaaacc	tctcatgaac	cctgtgagca	3780
agccaccgtc	tcaactcaatt	tgaatcttgg	cttcctctcaa	aagactggct	aatgttttgg	3840
aactctctgg	agtagacagc	actacatgta	cgtaagatag	gtacataaac	aactatttgg	3900
tttgagctga	tttttttcag	ctgcatttgc	atgtatggat	ttttctcacc	aaagacgatg	3960
acttcaagta	ttagtaaaat	aattgtacag	ctctcctgat	tatacttctc	tgtgacattt	4020
catttcccag	gctattttctt	ttggtaggat	ttaaaactaa	gcaattcagt	atgatctttg	4080
tccctcattt	tctttcttat	tctttttgtt	tgtttgtttg	tttgtttttt	tcttgaggca	4140
gagtcctctc	ctgtcgccca	ggctggagtg	cagtggcgcc	atctcagctc	attgcaacct	4200
ctgccacctc	cgggttcaag	agattctcct	gcctcagcct	cccgagtagc	tgggattaca	4260
gggtgccacc	accacaccog	gctaattttt	tgtattttta	gtagaggtgg	ggtttcacca	4320
tgttggccag	gctggtcttg	agctcctgac	ctcaggatgt	ccacctgcct	cggcctacca	4380
aagagctggg	ataacagggt	tgaccaccca	tgcccggccc	attttttttt	tcttattctg	4440
ttaggagtg	gagtgttaact	agcagtataa	tagttcaatt	ttcacacagt	ggtaaaagt	4500
tccctataat	tcaatcagat	tttgctccag	ggttcagttc	tgtttttagga	aatactttta	4560
ttttcagttt	aatgatgaaa	tattagagtt	gtaatatgtc	ctttatgatt	atccaccttt	4620
ttaacctaaa	agaatgaaag	aaaaatatgt	ttgcaatata	attttatgg	tgtatgttaa	4680
cttaattcat	tatggtggcc	tccagtttgc	tgttgttagt	tatgacagca	gtagtgcatt	4740
taccatttca	attcagatta	cattcctata	tttgatcatt	gtaaaactgac	tgtttacatt	4800
gtattaaaaa	cagtggatat	tttaaagaag	ctgtacggct	tatatctagt	gctgtctctt	4860
aagactatta	aattgatata	acatatttta	aagtaaatat	tacctaaatg	aatttttgaa	4920
attacaaata	cacgtgttaa	aactgtcgtt	gtgttcaacc	atttctgtac	atacttagag	4980
ttaactgttt	tgccaggctc	tgtatgccta	ctcataatat	gataaaagca	ctcatcta	5040
gctctgtaaa	tagaagtcag	tgctttccat	cagactgaac	tctcttgaca	agatgtggat	5100
gaaattcttt	aagtaaaatt	gtttactttg	tcatacattt	acagatcaaa	tgtagctcc	5160
caaagcaatc	atatggcaaa	gataggtata	tcatagtttg	cctattagct	gctttgtatt	5220
gctattatta	taaatagact	tcacagtttt	agacttgctt	aggtgaaatt	gcaattcttt	5280
ttactttcag	tcttagataa	caagtcttca	attatagtac	aatcacacat	tgttaggaa	5340
tgcatcatta	ggcgattttg	tcattatgca	aacatcatag	agtgtactta	cacaaacct	5400
gatagtatag	cctttatgta	cctaggccgt	atggtatagt	ctgttgctcc	tagggccaaa	5460
acctgtacaa	ctgttactgt	actgaatact	atagacagtt	gtaacacagt	ggtaaatatt	5520
tatctaaata	tatgcaaaca	gagaaaaggt	acagtaaaag	tatggtataa	aagataatgg	5580
tatacctgtg	taggccactt	accacgaatg	gagcttgacg	gactagaagt	tgtctgggt	5640
gagtcagtg	gtgagtgggt	aattaatgtg	aaggcctaga	acactgtaca	ccactgtaga	5700
ctataaacac	agtacgtga	agctacacca	aatttatctt	aacagttttt	cttcaataaa	5760
aaattataac	tttttaactt	tgtaaacttt	ttaatttttt	aactttttaa	atacttagct	5820

-continued

tgaacacaaa	atacattgta	tagctatata	aaaatatattt	ttctttgtat	ccttattcta	5880
gaagcttttt	tctattttct	attttaaatt	ttttttttta	cttgtagtc	gtttttgtta	5940
aaaactaaaa	cacacacact	ttcacctagg	catagacagg	attaggatca	tcagtatcac	6000
tcccttcac	ctcactgect	tccacctcca	catcttgtec	cactggaagg	tttttagggg	6060
caataacaca	catgtagctg	tcacctatga	taacagtgtc	ttctgttgaa	tacctcctga	6120
aggacttgcc	tgaggctggt	ttacatttaa	cttaaaaaaa	aaaaagtag	aaggagtgca	6180
ctctaaaata	acaataaaag	gcatagtata	gtgaatacat	aaaccagcaa	tgtagtagtt	6240
tattatcaag	tgtgtgacac	tgtaataatt	gtatgtgcta	tactttaaat	aacttgcaaa	6300
atagtactaa	gaccttatga	tggttacagt	gtcactaagg	caatagcata	ttttcaggtc	6360
cattgtaatc	taatgggact	accatcatat	atgcagtcta	ccattgactg	aaacgttaca	6420
tggcacataa	ctgtatttgc	aagaatgatt	tgttttacat	taatatcaca	taggatgtac	6480
cttttttagag	tggatgttt	atgtggatta	agatgtacaa	gttgagcaag	gggaccaaga	6540
gccctgggtt	ctgtcttggg	tgtgagcgtt	tatgttcttc	tcctcatgtc	tgttttctca	6600
ttaaattcaa	aggcttgaac	gggccctatt	tagcccttct	gttttctacg	tgttctaaat	6660
aactaaagct	tttaatttct	agccatttag	tgtagaactc	tctttgcagt	gatgaaatgc	6720
tgtattgggt	tcttggctag	catattaaat	atttttatct	ttgtcttgat	acttcaatgt	6780
cgttttaaac	atcaggatcg	ggcttcagta	ttctcataac	cagagagtcc	actgaggata	6840
caggactggt	tgccattttt	ttgttatggc	tccagacttg	tggattttcc	atgtcttttt	6900
tttttttttt	ttttttgacc	tttttagcgg	tttaaagtat	ttctgttggt	aggtgttgta	6960
ttacttttct	aagattactt	aacaaagcac	cacaaactga	gtggctttta	acaacagcaa	7020
tttattctct	cacaattcta	gaagctagaa	gtccgaaatc	aaagtgttga	caggggcatg	7080
atcttcaaga	gagaagactc	tttccttgcc	tcttcctggc	ttctgggtgt	taccagcaat	7140
cctgagtgtt	cctttcttgc	cttgtagttt	caacaatcca	gtatctgcct	ttgtcttca	7200
catggctgtc	taccatttgt	ctctgtgtct	ccaaatctct	ctccttataa	acacagcagt	7260
tattggatta	ggccccactc	taatccagta	tgacccatt	ttaacatgat	tacacttatt	7320
tctagataag	gtcacattca	cgtacaccaa	gggttaggaa	ttgaacatat	ctttttgggg	7380
gacacaattc	aaccacaaag	tgctagcttc	tagctgagcc	tttcccttcc	tgtttttctc	7440
cttttttagtt	gctatgggtt	agggggccaaa	tctccagtca	tactagaatt	gcacatggac	7500
tggatatttg	ggaatactgc	gggtctatcc	tatgagcttt	agtatgtaac	atttaatatc	7560
agtgtaaaga	agcccttttt	taagttattt	ctttgaattt	ctaaatgtat	gccctgaata	7620
taagtaacaa	gttaccatgt	cttgtaaaat	gatcatatca	acaacatttt	aatgtgcacc	7680
tactgtgcta	gttgaatgtc	tttatcctga	taggagataa	caggattcca	catctttgac	7740
ttaagaggac	aaaccaaata	tgtctaaatc	atttgggggt	ttgatggata	tctttaaatt	7800
gctgaacctc	atcattgggt	tcatatgtca	ttgttttagat	atctccggag	catttggtata	7860
atgtgacagt	tggatgcag	tgatgtcgac	tctttgccca	ccgccatctc	cagctgttgc	7920
caagacagag	attgctttta	gtggcaaatc	acctttatta	gcagctactt	ttgcttactg	7980
ggacaatatt	cttggtccta	gagtaaggca	catttgggct	ccaagacag	aacaggtact	8040
tctcagtgat	ggagaaataa	cttttcttgc	caaccacact	ctaaatggag	aaatccttcg	8100

-continued

aaatgcagag agtgggtgcta tagatgtaaa gttttttgtc ttgtctgaaa agggagtgat	8160
tattgtttca ttaatctttg atggaaactg gaatggggat cgcagcacat atggactatc	8220
aattatactt ccacagacag aacttagttt ctacctccca cttcatagag tgtgtgttga	8280
tagattaaca catataatcc ggaaaggaag aatatggatg cataaggtaa gtgatttttc	8340
agcttattaa tcatgttaac ctatctgttg aaagcttatt ttctggtaca tataaatctt	8400
atTTTTTTaa ttatatgcag tgaacatcaa acaataaatg ttattttatt tgcatttacc	8460
ctattagata caaatacatc tggctcgata cctgtcatct tcatattaac tgtggaaggt	8520
acgaaatggt agctcccat tatagatgaa aagctaaagc ttagacaaat aaagaaactt	8580
ttagaccctg gattcttctt gggagccttt gactetaata ccttttgttt ccctttcatt	8640
gcacaattct gtcttttgct tactactatg tgtaagtata acagttcaaa gtaatagttt	8700
cataagctgt tggctcatgta gcctttggtc tctttaacct ctttgccaag tcccaggtt	8760
cataaaatga ggagggtgaa tggaatggtt cccaagagaa ttcttttaa tcttacagaa	8820
attattgttt tcctaaatcc tgtagtgaa tatataatgc tatttacatt tcagtatagt	8880
tttgatgtat ctaagaaca cattgaatc tccttctgt gttccagttt gatactaacc	8940
tgaaagtcca ttaagcatta ccagttttaa aaggcttttg cccaatagta aggaaaaata	9000
atatctttta aaagaataat tttttactat gtttgcaggc ttacttcctt ttttctcaca	9060
ttatgaaact cttaaaatca ggagaatctt ttaaacaaca tcataatgtt taatttgaaa	9120
agtgcagtc attcttttcc tttttgaaac tatgcagatg ttacattgac tgttttctgt	9180
gaagtatatc ttttttcaat gcagaataaa ggttggtttg attttatttt gtattgttta	9240
tgagaacatg catttggttg gttaatctc tacccctgcc cccatttttt ccctaaagta	9300
gaaagtattt ttcttggtga ctaaaact acacaagaac atgtctattg aaaaataagc	9360
aagtatcaaa atgttggtgg ttgttttttt aaataaattt tctcttgctc aggaaagaca	9420
agaaaatgct cagaagatta tcttagaagg cacagagaga atggaagatc aggtatatgc	9480
aaattgcata ctgtcaaatg tttttctcac agcatgtatc tgtataaggt tgatggctac	9540
atttgtcaag gccttggaaga catatgaata agcctttaat ggagctttta tggaggtgta	9600
cagaataaac tggaggaaga ttcccatatc ttaaacccaa agagttaaat cagtaaacaa	9660
aggaaaatag taattgcac tacaaattaa tatttgcctc cttttttttt ctgtttgccc	9720
agaataaatt ttggataact tgttcatagt aaaaataaaa aaaattgtct ctgatatgtt	9780
ctttaaggta ctacttctcg aacctttccc tagaagtagc tgtaacagaa ggagagcata	9840
tgtacccctg aggtatctgt ctgggggtga ggcccaggtc cacacaatat ttcttctaag	9900
tcttatgttg tatcgtaag actcatgcaa ttacatttt attccataac tattttagta	9960
ttaaaatttg tcagtgatat ttcttaccct ctctctagg aaaatgtgcc atgtttatcc	10020
cttggtttg aatgccctc aggaacagac actaagagtt tgagaagcat gggtacaagg	10080
gtgtggcttc ccctgcggaa actaagtaca gactatttca ctgtaaagca gagaaagtct	10140
tttgaaggag aatctccagt gaagaaagag ttcttcactt ttacttccat ttctcttgt	10200
gggtgacct caatgctct tgtaaaactc caatatTTta aacatggctg ttttgccttt	10260
ctttgcttct ttttagcatg aatgagacag atgatacttt aaaaaagtaa ttaaaaaaaa	10320
aaacttgta aaatacatgg ccataatata gaacccaata caatgatctc ctttaccaaa	10380

-continued

ttgttatggt	tgtacttttg	tagatagctt	tccaattcag	agacagttaa	tctgtgtaaa	10440
ggtctgactt	aacaagaaaa	gatttccctt	tacccaaaaga	atcccagtc	ttatttgctg	10500
gtcaataagc	agggtcccca	ggaatggggt	aactttcagc	acccctaac	ccactagtta	10560
ttagtagact	aattaagtaa	acttatcgca	agttgaggaa	acttagaacc	aactaaaatt	10620
ctgcttttac	tgggattttg	ttttttcaaa	ccagaaacct	ttacttaagt	tgactactat	10680
taatgaattt	tggtctctct	tttaagtgt	cttcttaaaa	atgttatctt	actgctgaga	10740
agttcaagtt	tgggaagtac	aaggaggaat	agaaacttaa	gagattttct	tttagagcct	10800
cttctgtatt	tagccctgta	ggattttttt	tttttttttt	tttttgggtg	ttgttgagct	10860
tcagtgaggc	tattcattca	cttatactga	taatgtctga	gatactgtga	atgaaatact	10920
atgtatgctt	aaacctaa	ggaaatattt	tcccaaaatt	attcttcccg	aaaaggagga	10980
gttgcccttt	gattgagttc	ttgcaaatct	cacaacgact	ttattttgaa	caatactggt	11040
tggggatgat	gcattagttt	gaaacaactt	cagttgtagc	tgctcatctga	taaaattgct	11100
tcacagggaa	ggaaatttaa	cacggatcta	gtcattattc	ttgttagatt	gaatgtgtga	11160
attgtaattg	taaacaggca	tgataattat	tactttaaaa	actaaaaaca	gtgaatagtt	11220
agttgtggag	gttactaaag	gatgggtttt	ttttaataaa	aactttcagc	attatgcaaa	11280
tgggcataatg	gcttaggata	aaacttcag	aagtagcatc	acattttaat	tctcaagcaa	11340
cttaataata	tggggctctg	aaaaactgg	taaggttact	ccaaaaatgg	ccctgggtct	11400
gacaaagatt	ctaacttaaa	gatgcttatg	aagactttga	gtaaaatcat	ttcataaaat	11460
aagtgaggaa	aaacaactag	tattaaattc	atcttaata	atgtatgatt	taaaaaatat	11520
gtttagctaa	aaatgcatag	tcatttgaca	atttcattta	tatctcaaaa	aattttactta	11580
accaagttgg	tcacaaaact	gatgagactg	gtgggtgtag	tgaataaatg	agggaccatc	11640
catatttgag	acactttaca	tttgatgatg	gttatactga	attttcagtt	tgattctata	11700
gactacaaat	ttcaaaatta	caatttcaag	atgtaataag	tagtaatatc	ttgaaatagc	11760
tctaaagggg	atttttctgt	tttattgatt	cttaaaatat	atgtgctgat	tttgatttgc	11820
atttggttag	attatacttt	tatgagtatg	gaggtttagt	attgattcaa	gttttcctta	11880
cctatttggt	aaggatttca	aagtcttttt	gtgcttggtt	ttcctcat	ttaaatatga	11940
aatatattga	tgaccttta	caaatttttt	ttatctcaaa	ttttaaagga	gatcttttct	12000
aaaagaggca	tgatgactta	atcattgcat	gtaacagtaa	acgataaacc	aatgattcca	12060
tactctctaa	agaataaaag	tgagcttttag	ggccgggcat	ggtcagaaat	ttgacaccaa	12120
cctggccaac	atggcgaaac	ccgctctcta	ctaaaaatac	aaaaatcagc	cgggcatggt	12180
ggcggcacct	atagtcaccag	ctacttggga	ggatgagaca	ggagagtcac	ttgaacctgg	12240
gaggagaggt	tgcagtgagc	tgatgacacg	ccattgcact	ccagcctgag	caatgaaagc	12300
aaaactccat	ctcaaaaaaa	aaaaaagaaa	agaaagaata	aaagtgagct	ttggattgca	12360
tataaatcct	ttagacatgt	agtagacttg	tttgatactg	tgtttgaaca	aattacgaag	12420
tattttcatc	aaagaatggt	attgtttgat	gttattttta	ttttttattg	cccagcttct	12480
ctcatattac	gtgattttct	tcacttcatg	tcactttatt	gtgcagggtc	agagtattat	12540
tccaatgctt	actggagaag	tgattcctgt	aatggaactg	ctttcatcta	tgaaatcaca	12600
cagtgttcct	gaagaaatag	atgtaagttt	aaatgagagc	aattatacac	tttatgagtt	12660

-continued

ttttggggtt	atagtattat	tatgtatatt	attaatatcc	taattttaat	agtaaggact	12720
ttgtcataca	tactattcac	atacagtatt	agccacttta	gcaaataagc	acacacaaaa	12780
tcctggattt	tatggcaaaa	cagaggcatt	tttgatcagt	gatgacaaaa	ttaaattcat	12840
tttgtttatt	tcattacttt	tataattcct	aaaagtggga	ggatcccagc	tcttatagga	12900
gcaattaata	tttaatgtag	tgtcttttga	aacaaaactg	tgtgccaaag	tagtaaccat	12960
taatggaagt	ttacttgtag	tcacaaattt	agtttcttta	atcatttggt	gaggacgttt	13020
tgaatcacac	actatgagtg	ttaagagata	ccttttaggaa	actattcttg	ttgttttctg	13080
atthttgtcat	ttaggttagt	ctcctgattc	tgacagctca	gaagaggaag	ttgttcttgt	13140
aaaaattggt	taacctgctt	gaccagcttt	cacatttggt	cttctgaagt	ttatggtagt	13200
gcacagagat	tgthtttttg	ggagtcttga	ttctcggaaa	tgaaggcagt	gtgttatatt	13260
gaatccagac	ttccgaaaac	ttgtatatta	aaagtgttat	ttcaacacta	tgttacagcc	13320
agactaatth	ttttatthtt	tgatgcattt	tagatagctg	atacagtact	caatgatgat	13380
gatattgggt	acagctgtca	tgaaggcttt	cttctcaagt	aagaatttht	ctthtcataa	13440
aagctggatg	aagcagatac	catcttatgc	tcacctatga	caagatttgg	aagaaagaaa	13500
ataacagact	gtctacttag	attgttctag	ggacattacg	tatttgaact	gttgcttaaa	13560
tttgtgttat	thttcactca	ttatthttct	atatatattt	ggtgttatth	catttgctat	13620
ttaaagaaac	cgagtthcca	tcccagacaa	gaaatcatgg	ccccttgctt	gattctgggt	13680
tcttgthtta	cttctcatta	aagctaacag	aatcctthca	tattaagttg	tactgtagat	13740
gaacttaagt	tatttaggcg	tagaacaaaa	ttattcatat	ttatactgat	ctthttccat	13800
ccagcagtg	agthtagtac	ttaagagtht	gtgcccttaa	accagactcc	ctggattaat	13860
gctgtgtacc	cgtgggcaag	gtgcctgaat	tctctataca	cctatttctc	catctgtaaa	13920
atggcaataa	tagtaatagt	acctaattgt	tagggthgtt	ataagcattg	agtaagataa	13980
ataatataaa	gcacttagaa	cagtgccctg	aacataaaaa	cacttaataa	tagctcatag	14040
ctaacatttc	ctattttacat	ttcttctaga	aatagccagt	atttgthtag	tgccacatg	14100
ttagthcctt	tactagthgc	thtacatgta	ttatcttata	ttctgthtta	aagthttctc	14160
acagthtacag	atthttcatga	aatthttact	ttaataaaa	agaagtaaaa	gtataaagta	14220
thcactthtta	tgthtcacagt	ctthttcctt	aggctcatga	tggagtatca	gaggcatgag	14280
tgtgtthtaac	ctaagagcct	taatggcttg	aatcagaagc	actthtagtcc	tgtatctgtt	14340
cagtgtcagc	ctthtcataca	tcattthtaaa	tcccatthga	ctthtaagtaa	gtcacttaat	14400
ctctctacat	gtcaattthct	tcagctataa	aatgatggta	thtcaataaa	taaatacatt	14460
aattaaatga	tattatactg	actaattggg	ctgtthttaag	gctcaataag	aaaattthctg	14520
tgaaaggctc	ctagaaaaatg	taggttcccta	tacaaaaaaa	agataacatt	gtgcttatag	14580
cttcgggtgtt	tatcatataa	agctattthctg	agthatttga	agagctcacc	tactthtttt	14640
tgthtttagt	thgtthaaatt	gtthttatagg	caatgtthtt	aatctgttht	ctthtaactta	14700
cagtgccatc	agctcacact	tgcaaacctg	tggtgtgtcc	gttgtagtag	gtagcagtg	14760
agagaaagta	aataaggtag	thtattthtat	aatctagcaa	atgatttgac	tctthtaagac	14820
tgatgatata	tcattggattg	tcattthaaat	ggtaggttgc	aattaaaaatg	atctagtagt	14880
ataaggaggc	aatgtaatct	catcaaatg	ctaagacacc	thgtggcaac	agtgagtht	14940

-continued

aaataaactg	agtaagaatc	atttatcagt	ttattttgat	agctcggaaa	taccagtgtc	15000
agtagtgat	aatgggtttt	gagaatatat	taaaatcaga	tataaaaaa	aaattactct	15060
tctatttccc	aatgttatct	ttaacaaatc	tgaagatagt	catgtacttt	tggtagtagt	15120
tccaagaaa	tggtatttgt	ttattcatct	tgatttcatt	gtcttcgctt	tccttctaaa	15180
tctgtocctt	ctagggagct	attgggatta	agtggtcatt	gattattata	ctttattcag	15240
taatgtttct	gaccttttcc	ttcagtgcga	cttgagttaa	ttaaggatta	atgaacagtt	15300
acatttccaa	gcattagcta	ataaactaaa	ggattttgca	cttttcttca	ctgaccatta	15360
gttagaaa	ggttcagagat	aagtatgtgt	atctttcaat	ttcagcaaac	ctaatttttt	15420
aaaaaaagt	ttacatagga	aatatgttgg	aaatgatact	ttacaaagat	attcataatt	15480
tttttttgta	atcagctact	ttgtatat	acatgagcct	taatttatat	ttctcatata	15540
accatttatg	agagcttagt	atacctgtgt	catttatattg	catctacgaa	ctagtgcctt	15600
tattccttct	gttacctcaa	acaggtggct	ttccatctgt	gatctccaaa	gccttaggtt	15660
gcacagagtg	actgccgagc	tgctttatga	aggagaaaag	gctccatagt	tgagtggtt	15720
tttttttttt	ttttaaacat	ttttcccatc	ctccatcctc	ttgagggaga	atagcttacc	15780
ttttatcttg	ttttaatttg	agaaagaagt	tgccaccact	ctaggttgaa	aaccactcct	15840
ttaacataat	aactgtggat	atgggttgaa	tttcaagata	gttacatgcc	tttttatttt	15900
tcctaataga	gctgtaggtc	aaatattatt	agaatcagat	ttctaaatcc	cacccaatga	15960
cctgcttatt	ttaaatcaaa	ttcaataatt	aattctcttc	tttttgagg	atctggacat	16020
tctttgatat	ttcttacaac	gaatttcatt	tgtagacca	ctaaacagaa	gctataaaag	16080
tgcatgggc	aaataagtct	gagaaagtct	gcagatgata	taattcacct	gaagagtcac	16140
agtagtagc	caaatgttaa	agggtttgag	atgccataga	gtaaatctac	caagcatttt	16200
ctaaatttat	ttgaccacag	aatccctatt	ttaagcaaca	actgttacat	cccatggatt	16260
ccaggtgact	aaagaatact	tatttcttag	gatatgtttt	attgataata	acaattaaaa	16320
tttcagatat	ctttcataag	caaatcagtg	gtctttttac	ttcatgtttt	aatgctaaaa	16380
tattttcttt	tatagatagt	cagaacatta	tgcttttttc	tgactccagc	agagagaaaa	16440
tgctccaggt	tatgtgaagc	agaatcatca	tttaaatatg	agtcagggct	ctttgtacaa	16500
ggcctgctaa	aggtagattt	tctagttatc	acaagtgaag	ccacttttct	aaaatcattt	16560
ttgagactct	ttatagacaa	atcttaaata	ttagcattta	atgtatctca	tattgacatg	16620
cccagagact	gacttccttt	acacagttct	gcacatagac	tatatgtctt	atggatttat	16680
agttagtagc	atcagtgaag	caccatagaa	taccttttgt	gttcagggtg	ggccctgtt	16740
cctacatgtc	tagcctcagg	actttttttt	ttttaacaca	tgcttaaatc	aggttgacaa	16800
tcaaaaaata	gatcatttct	ttttaactaa	atagatttga	attttattga	aaaaaaattt	16860
taaacatctt	taagaagctt	ataggattta	agcaattcct	atgtatgtgt	actaaaaat	16920
atatatttct	atatataata	tatatagaa	aaaaattgta	tttttctttt	atttgagtct	16980
actgtcaagg	agcaaaacag	agaaatgtaa	attagcaatt	atttataata	cttaaaggga	17040
agaaagtgtg	tcaccttggt	gaatctatta	ttgttatttc	aattatagtc	ccaagacgtg	17100
aagaaatagc	tttctaatg	gttatgtgat	tgtctcatag	tgactacttt	cttgaggatg	17160
tagccacggc	aaaatgaat	aaaaaaattt	aaaaattggt	gcaaatacaa	gttatattag	17220

-continued

gcttttgtgc	attttcaata	atgtgctgct	atgaactcag	aatgatagta	tttaaatata	17280
gaaactagtt	aaaggaaacg	tagtttctat	ttgagttata	catatctgta	aattagaact	17340
tctctgttta	aaggcataat	aaagtgttta	atacttttgt	ttctcagca	cctctcatt	17400
taattatata	attttagttc	tgaaaggac	ctataccaga	tgctagagg	aaatttcaaa	17460
actatgatct	aatgaaaaaa	tatttaatag	ttctccatgc	aaatacaaat	catatagttt	17520
tccagaaaat	acctttgaca	ttatacaaag	atgattatca	cagcattata	atagtaaaaa	17580
aatggaaata	gcctctttct	tctgttctgt	tcatagcaca	gtgcctcata	cgcagtaggt	17640
tattattaca	tggttaactgg	ctaccccaac	tgattaggaa	agaagtaaat	ttgttttata	17700
aaaatacata	ctcattgagg	tgcatagaat	aattaagaaa	ttaaaagaca	cttgtaattt	17760
tgaatccagt	gaatacccac	tgtaaatatt	tggtatatct	ctttctagtc	ttttttccc	17820
ttttgcatgt	attttcttta	agactcccac	ccccactgga	tcatctctgc	atgttctaata	17880
ctgctttttt	cacagcagat	tctaagcctc	tttgaatata	aacacaaact	tcaacaactt	17940
catctataga	tgccaaataa	taaattcatt	tttatttact	taaccacttc	ctttggatgc	18000
ttaggtcatt	ctgatgtttt	gctattgaaa	ccaatgctat	actgaacact	tctgtcacta	18060
aaactttgca	cacactcatg	aatagcttct	taggataaat	ttttagagat	ggatttgcta	18120
aatcagagac	cattttttta	aattaaaaaa	caattattca	tatcgtttgg	catgtaagac	18180
agtaaatttt	ccttttattt	tgacaggatt	caactggaag	ctttgtgctg	cctttccggc	18240
aagtcatgta	tgctccatat	cccaccacac	acatagatgt	ggatgtcaat	actgtgaagc	18300
agatgccacc	ctgtcatgaa	catatttata	atcagcgtag	atacatgaga	tccgagctga	18360
cagccttctg	gagagccact	tcagaagaag	acatggctca	ggatacgatc	atctacactg	18420
acgaaagctt	tactcctgat	ttgtacgtaa	tgctctgcct	gctggtagctg	tagtcaagca	18480
atatgaaatt	gtgtctttta	cgaataaaaa	caaaacagaa	gttgcattta	aaaagaaaga	18540
aatattacca	gcagaattat	gcttgaagaa	acatttaata	aagcattttt	ttcttaaatg	18600
ttcttctttt	tccatacaat	tgtgtttacc	ctaaaaatag	taagattaac	ccttaagta	18660
aatatttaac	tatttgttta	ataaatatat	attgagctcc	taggcaactgt	tctaggtacc	18720
gggcttaata	gtggccaacc	agacagcccc	agccccagcc	cctacattgt	gtatagtcta	18780
ttatgtaaca	gttattgaat	ggacttatta	acaaaaccaa	agaagtaatt	ctaagtcttt	18840
tttttcttga	catatgaata	taaaatacag	caaaactgtt	aaaatatatt	aatggaacat	18900
ttttttactt	tgcattttat	attgtttatc	acttcttatt	tttttttaaa	aaaaaaagcc	18960
tgaacagtaa	attcaaaaag	aaaagtaatg	ataattaatt	gttgagcatg	gacccaactt	19020
gaaaaaaaa	atgatgatga	taaatctata	atcctaaaac	cctaagtaaa	cacttaaaag	19080
atgttctgaa	atcaggaaaa	gaattatagt	atacttttgt	gtttctcttt	tatcagttga	19140
aaaaaggcac	agtagctcat	gctgtgaaga	acagagcttt	gggagtgcga	ggcaggcgga	19200
tcacttgagg	ccaggagtgc	cagaccagcc	tgggcaacat	agtgaaaccc	catctctaca	19260
aaaaataaaa	aagaattatt	ggaatgtgtt	tctgtgtgcc	tgtaatccta	gctattccga	19320
aagctgaggc	aggaggatct	tttgagccca	ggagtgtgag	gttacaggga	gttatgatgt	19380
gccagtgtac	tccagcctgg	ggaacaccga	gactctgtct	tatttaaaaa	aaaaaaaaaa	19440
aaaatgcttg	caataatgcc	tggcacatag	aaggtaacag	taagtgttaa	ctgtaataac	19500

-continued

ccaggtctaa	gtgtgtaagg	caatagaaaa	attggggcaa	ataagcctga	cctatgtatc	19560
tacagaatca	gtttgagctt	aggtaacaga	cctgtggagc	accagtaatt	acacagtaag	19620
tgtaaaccaa	aagcatagaa	taggaatata	ttgttcaagg	gacccccage	cttatacatc	19680
tcaaggtgca	gaaagatgac	ttaatatagg	acccattttt	tcctagttct	ccagagtttt	19740
tattggttct	tgagaaagta	gtagggggaat	gttttagaaa	atgaattggg	ccaactgaaa	19800
ttacatgtca	gtaagttttt	atatattggg	aaattttagt	agacatgtag	aagttttcta	19860
attaatctgt	gccttgaaac	attttctttt	ttcctaaagt	gcttagtatt	ttttccgttt	19920
tttgattggg	tacttgggag	cttttttgag	gaaattttag	gaactgcaga	atgggtttgc	19980
aaccatttgg	tatttttggt	ttgtttttta	gaggatgtat	gtgtatttta	acattttctta	20040
atcattttta	gccagctatg	ttgtttttgc	tgatttgaca	aactacagtt	agacagctat	20100
tctcattttg	ctgatcatga	caaaataata	tctgaattt	ttaaattttg	catccagctc	20160
taaattttct	aaacataaaa	ttgtccaaaa	aatagtattt	tcagccacta	gattgtgtgt	20220
taagtctatt	gtcacagagt	cattttactt	ttaagtatat	gtttttacat	gttaattatg	20280
tttgttattt	ttaattttta	cttttttaaa	taattccagt	cactgccaat	acatgaaaaa	20340
ttggtcactg	gaattttttt	ttgactttt	attttaggtt	catgtgtaca	tgtgcagggtg	20400
tgttatacag	gtaaattgag	tgcatgagg	gtttgggtga	caggtgattt	cattaccag	20460
gtaataagca	tagtacccaa	taggtagttt	tttgatcttc	acccttctcc	caccctcaag	20520
taggcccctg	tggtgctggt	tccttctttg	tgcccatgta	tactcagttg	ttagctccca	20580
cttagaagtg	agaacatgag	gtagttgggt	ttctgttcct	ggattagtgc	acttaggata	20640
atgacctcta	gctccatctg	gtttttatgg	ctgcatagta	ttccatgggtg	tatatgtatc	20700
acattttctt	tatccagttc	accattgata	ggcatttagg	ttgattccct	gtctttgtta	20760
tcataaatag	tgctgtgatg	aacatacaca	tgcatgtgtc	tttatggtag	aaaaatttgt	20820
attcctttag	gtacatatag	aataatgggg	ttgctagggg	gaatggtagt	tctattttca	20880
gttatttgag	aaactctcaa	actgcttttc	ataatagcta	aactaattta	cagtcccgcc	20940
agcagtgat	aagtgttccc	ttttctccac	aaccttgcca	acatctgtga	ttttttgact	21000
ttttaataat	agccattcct	agagaattga	tttgcaattc	tctatttagt	atattaagca	21060
ttttttcata	tgttttttag	ctgtctgtat	atattcttct	gaaaaatttt	catgtccttt	21120
gccagttttg	tagtgggggtg	gggtgttttt	tgcttggtta	ttagttttta	gttccttcca	21180
gattctgcat	atccctttgt	tggtacatg	gtttgcagat	atttttctcc	cattgtgtag	21240
gttgcttttt	actctgttga	tagtttcttt	tgccatgcag	gagctcggtta	ggteccattt	21300
gtgtttgttt	ttgttgaggt	tgcttttggt	gtcttcatca	taaaatctgt	gccagggcct	21360
atgtccagaa	tggtatttcc	taggttggtc	tccaggggtt	ttacaatttt	agatttttacg	21420
tttatgtctt	taatccatct	tgagttgatt	tttgtatatg	gcacaaggaa	gggggtccagt	21480
ttcaactcaa	ttcctatggc	tagcaattat	cccagcacca	tttattgaat	acggagtcct	21540
ttccccattg	cttggttttt	gtcaactttg	ttgaagatca	gatgggtgtga	agtgtgtggc	21600
tttatttctt	ggctctctat	tctccattgg	tctatgtgtc	tggtttttata	acagtaacct	21660
gtgtttcagg	ttcctatagc	cttttagtat	aaaatcggtc	aatgtgatgc	ctccagcttt	21720
gttctttttg	cttaggattg	ctttggctat	ttgggtctct	ttttgggtcc	atattaattt	21780

-continued

taaaacagtt	ttttctggtt	tgtgaagga	tatcattggt	agtttatagg	aatagcattg	21840
aatctgtaga	ttgctttggg	cagtatggcc	attttaacaa	tattaattct	tcctatctat	21900
gaatatggaa	tgtttttcca	tgtgtttgtg	tcctctcttt	atacctgatg	tataaagaaa	21960
agctgggtatt	attcctactc	aatctgttcc	aaaaaattga	ggaggaggaa	ctcttcctta	22020
atgaggccag	catcattctg	ataccaaaac	ctggcagaga	cacaacagaa	aaaagaaaac	22080
ttcaggccaa	tatccttgat	gaatatagat	gcaaaaatcc	tcaacaaaat	actagcaaac	22140
caaatccagc	agcacatcaa	aaagctgata	tactttgatc	aagtaggctt	tatccctggg	22200
atgcaagggt	ggttcaacat	acacaaatca	ataagtgtga	ttcatcacat	aaacagagct	22260
aaaaacaaaa	accacaagat	tatctcaata	ggtagagaaa	aggttgtaaa	taaaatttaa	22320
catcctccat	gttaaaaaac	ttcagtaggt	caggtgtagt	gactcacacc	tgtaatccca	22380
gcactttggg	aggccaaggc	gggcatatct	cttaagccca	ggagtccaag	acgagcctag	22440
gcagcatggt	gaaaccccat	ctctacaaaa	aaaaaaaaaa	aaaaaatta	gcttggtatg	22500
gtgacatgca	cctatagtcc	cagctattca	ggaggttgag	gtgggaggat	tgtttgagcc	22560
cgggaggcag	aggttggcag	cgagctgaga	tcattgccacc	gcactccagc	ctgggcaacg	22620
gagtgagacc	ctgtctcaaa	aaagaaaaat	cacaacaat	cctaaacaaa	ctaggcattg	22680
aaggaacatg	cctcaaaaaa	ataagaacca	tctatgacag	acccatagcc	aatatcttac	22740
caaatgggca	aaagctggaa	gtattctcct	tgagaaccgt	aacaagacaa	ggatgtccac	22800
tctcaccact	ccttttcagc	atagttcttg	aagtcttagc	cagagcaatc	aggaaagaga	22860
aagaaagaaa	gacattcaga	taggaagaga	agaagtcaaa	ctattttctgt	ttgcaggcag	22920
tataattctg	tacctagaaa	atctcatagt	ctctgcccag	aaactcctaa	atctgttaaa	22980
aatttcagca	aagttttggc	attctctata	ctccaacacc	ttccaaagtg	agagcaaaat	23040
caagaacaca	gtcccatcca	caatagccgc	aaaacgaata	aaatacctag	gaatccagct	23100
aaccagggag	gtgaagatc	tctatgagaa	ttacaaaaca	ctgctgaaag	aaatcagaga	23160
tgacacaaac	aaatggaaat	gttctttttt	aacaccttgc	tttatctaata	tcacttatga	23220
tgaagatact	cattcagtgg	aacaggtata	ataagtccac	tcgattaaat	ataagcctta	23280
ttctctttcc	agagcccaag	aaggggcact	atcagtgcac	agtcataaat	gacgaaatgc	23340
taatatTTTT	cccttttacg	gtttctttct	tctgtagtgt	ggtacactcg	tttcttaaga	23400
taaggaaact	tgaactacct	tcctgtttgc	ttctacacat	acccattctc	tttttttgcc	23460
actctggtea	ggtataggat	gatccctacc	actttcagtt	aaaaactcct	cctcttacta	23520
aatgttctct	tacccctctg	cctgagttaga	acctagggaa	aatggaagag	aaaaagatga	23580
aaggagggtg	gggcctggga	agggaataag	tagtcctgtt	tgtttggtgtg	tttgctttag	23640
cacctgctat	atcctagggtg	ctgtgttagg	cacacattat	tttaagtggc	catttatatta	23700
ctactactca	ctctggtcgt	tgccaaggta	ggtagtactt	tcttgatag	ttgggtcatg	23760
ttacttacag	atggtgggct	tgttgaggca	aaccagtggt	ataatcatcg	gagtgtgttc	23820
tctaactcca	ctcaaatTTT	tcttcacatt	ttttggtttg	ttttggTTTT	tgatggtagt	23880
ggcttatttt	tgttgctgggt	ttgttttttg	tttttttttg	agatggcaag	aattggtagt	23940
tttattttatt	aattgcctaa	gggtctctac	tttttttaaa	agatgagagt	agtaaaatag	24000
attgatagat	acatacatac	ccttactggg	gactgcttat	attctttaga	gaaaaaatta	24060

-continued

catattagcc	tgacaaacac	cagtaaaatg	taaatatatc	cttgagtaaa	taaatgaatg	24120	
tatattttgt	gtctccaaat	atatatatct	atattcttac	aaatgtgttt	atatgtaata	24180	
tcaatttata	agaacttaaa	atgttggtc	aagtggagg	ttgtggaagg	tagcattata	24240	
tggccatttc	aacatttgaa	cttttttctt	ttcttcattt	tcttcttttc	ttcaggaata	24300	
tttttcaaga	tgtcttacac	agagacactc	tagtgaaagc	cttcctggat	caggtaaagt	24360	
ttgaacttga	gattgtcaga	gtgaatgata	tgacatgttt	tcttttttaa	tatatcctac	24420	
aatgcctgtt	ctatatattt	atattccctc	ggatcatgcc	ccagagttct	gctcagcaat	24480	
tgcagttaag	ttagttacac	tacagtcttc	agaagagtct	gtgagggcat	gtcaagtgca	24540	
tcattacatt	gggtgcctct	tgtcctagat	ttatgcttcg	ggaattcaga	cctttgttta	24600	
caatataata	aatattattg	ctatctttta	aagatataat	aataagatat	aaagttgacc	24660	
acaactactg	ttttttgaaa	catagaattc	ctggtttaca	tgtatcaaag	tgaaatctga	24720	
cttagccttt	acagatataa	tatatacata	tatatatcct	gcaatgcttg	tactatatat	24780	
gtagtacaag	tatatatata	tgtttgtgtg	tgtatatata	tatagtacga	gcatatatac	24840	
atattaccag	cattgtagga	tatatatatg	tttatatatt	aaaaaaaaag	tataaacctta	24900	
aaaccttatt	atgttatgta	gagtatatgt	tatatatgat	atgtaaaata	tataacatat	24960	
actctatgat	agagtgtaat	atatttttta	tatatatttt	aacatttata	aaatgataga	25020	
attaagaatt	gagtccta	at	ctgttttatt	agggtctttt	tgtagtgtct	ggctcttcta	25080
aagtgctctaa	atgatttttc	cttttgactt	attaatgggg	aagagcctgt	atattaacaa	25140	
ttaagagtgc	agcattccat	acgtcaaaca	acaaacattt	taattcaagc	attaacctat	25200	
aacaagtaag	tttttttttt	ttttttgaga	aaggagggtt	gtttatttgc	ctgaaatgac	25260	
tcaaaaaat	ttttgaaaca	tagtgactt	atttaaataa	catctttatt	gtttcattct	25320	
tttaaaaaat	atctacttaa	ttacacagtt	gaaggaaatc	gtagattata	tggaacttat	25380	
ttcttaatat	attacagttt	gttataataa	cattctgggg	atcaggccag	gaaactgtgt	25440	
catagataaa	gctttgaaat	aatgagatcc	ttatgtttac	tagaaatttt	ggattgagat	25500	
ctatgaggtc	tgtgacatat	tgcgaagttc	aaggaaaatt	cgtaggcctg	gaatttcacg	25560	
cttctcaagc	tgacataaaa	tcctccccc	ctccacctc	atcatatgca	cacattctac	25620	
tcctacccac	ccactccacc	ccttgcaaaa	gtacaggtat	atgaatgtct	caaaaccata	25680	
ggctcatctt	ctaggagctt	caatgttatt	tgaagatttg	ggcagaaaaa	attaagtaat	25740	
acgaaataac	ttatgtatga	gtttttaaag	tgaagtaaac	atggatgtat	tctgaagtag	25800	
aatgcaaaat	ttgaatgc	ttttaaagat	aaattagaaa	acttctaaaa	actgtcagat	25860	
tgtctgggcc	tggtggctta	tgcctgtaat	cccagcactt	tgggagtcgc	aggtgggtgg	25920	
atcacaaggt	caggagatcg	agaccatcct	gccaacatgg	tgaacccccg	tctctactaa	25980	
gtatacaaaa	attagctggg	cgtggcagcg	tgtgcctgta	atcccagcta	cctgggaggg	26040	
tgaggcagga	gaatcgcttg	aaccaggag	gtgtaggttg	cagtgaagtca	agatcgcgcc	26100	
actgcacttt	agcctgggtga	cagagctaga	ctccgtctca	aaaaaaaaaa	aaaatatcag	26160	
attgttccta	cacctagtgc	ttctatacca	cactcctgtt	agggggcatc	agtggaaatg	26220	
gttaaggaga	tgttttagtgt	gtattgtctg	ccaagcactg	tcaacactgt	catagaaact	26280	
tctgtacgag	tagaatgtga	gcaaattatg	tgttgaaatg	gttcctctcc	ctgcagggtct	26340	

-continued

ttcagctgaa	acctggctta	tctctcagaa	gtactttcct	tgacacagttt	ctacttgctc	26400
ttcacagaaa	agccttgaca	ctaataaaat	atatagaaga	cgatacgtga	gtaaaactcc	26460
tacacggaag	aaaaaccttt	gtacattggt	tttttggttt	gtttcctttg	tacattttct	26520
atatacataat	ttttgcgctt	cttttttttt	tttttttttt	tttttttcca	ttatttttag	26580
gcagaaggga	aaaagccct	ttaaatctct	tcggaacctg	aagatagacc	ttgatttaac	26640
agcagagggc	gatcttaaca	taataatggc	tctggctgag	aaaattaaac	caggcctaca	26700
ctcttttatc	tttggaagac	ctttctacac	tagtgtgcaa	gaacgagatg	ttctaataac	26760
tttttaaatg	tgtaacttaa	taagcctatt	ccatcacaa	catgatcgct	ggtaaagtag	26820
ctcagtgggt	tggggaaacg	ttccccgga	tcatactcca	gaattctgct	ctcagcaatt	26880
gcagttaagt	aagttacact	acagttctca	caagagcctg	tgaggggatg	tcagggtgat	26940
cattacattg	gggtgtctct	ttcctagatt	tatgcttttg	ggatacagac	ctatgtttac	27000
aatataataa	atattattgc	tatcttttaa	agatataata	ataggatgta	aacttgacca	27060
caactactgt	tttttgaaa	tacatgattc	atggtttaca	tgtgtcaagg	tgaaatctga	27120
gttggtcttt	acagatagtt	gactttctat	cttttggcat	tctttggtgt	gtagaattac	27180
tgtaataact	ctgcaatcaa	ctgaaaacta	gagcctttaa	atgatttcaa	ttccacagaa	27240
agaaagtgag	cttgaacata	ggatgagctt	tagaaagaaa	attgatcaag	cagatgttta	27300
attggaattg	attattagat	cctactttgt	ggatttagtc	cctgggatcc	agtctgtaga	27360
aatgtcta	agtctctat	agtccttgt	cctgggtgac	cacagttagg	gtgttttgtt	27420
tattttattg	ttcttgctat	tgttgatatt	ctatgtagtt	gagctctgta	aaaggaaatt	27480
gtattttatg	tttttagta	tgttgccaac	tttttaaatt	aattttcatt	atttttgagc	27540
caaattgaaa	tgtgcacctc	ctgtgccttt	tttctcctta	gaaaatctaa	ttacttgga	27600
caagttcaga	tttactgggt	cagtcatttt	catcttggtt	tcttcttgct	aagtcttacc	27660
atgtacctgc	tttggcaatc	attgcaactc	tgagattata	aaatgcctta	gagaatatac	27720
taactaataa	gatctttttt	tcagaaacag	aaaatagttc	cttgagtact	tccttcttgc	27780
atttctgcct	atgtttttga	agttgttgct	gtttgcctgc	aataggctat	aaggaatagc	27840
aggagaaaatt	ttactgaagt	gctgttttcc	taggtgctac	tttggcagag	ctaagttatc	27900
ttttgttttc	ttaatgcgtt	tggaccattt	tgctggctat	aaaataactg	attaatataa	27960
ttctaacaca	atgttgacat	tgtagttaca	caaacacaaa	taaatatttt	atttaaaatt	28020
ctggaagtaa	tataaaaggg	aaaatatatt	tataagaaag	ggataaagggt	aatagagccc	28080
ttctgcccc	caccacccaa	atttacacaa	caaaatgaca	tggtcgaatg	tgaaagggtca	28140
taatagcttt	cccatcatga	atcagaaaga	tgtggacagc	ttgatgtttt	agacaaccac	28200
tgaactagat	gactgttgta	ctgtagctca	gtcattttaa	aaatatataa	atactacctt	28260
gtagtgtccc	atactgtggt	ttttacatgg	tagattctta	tttaagtgtc	aactggttat	28320
tttctttggc	tggtttattg	tactgttata	cagaatgtaa	gttgtacagt	gaaataagtt	28380
attaaagcat	gtgtaaacat	tgttatatat	cttttctcct	aaatggagaa	ttttgaataa	28440
aatatatttg	aaattttgct	tctttcagtt	gttcattcag	aaaaaatac	tatgatattt	28500
gaagactgat	cagcttctgt	tcagctgaca	gtcatgctgg	atctaaactt	tttttaaaat	28560
taattttgtc	ttttcaaaga	aaaaatattt	aaagaagctt	tataatataa	tcttatgtta	28620

-continued

```

aaaaaacctt ctgcttaact ctctggattt cattttgatt tttcaaatta tatattaata 28680
tttcaaatgt aaaatactat ttagataaat tgttttttaa cattottatt attataatat 28740
taatataacc taaactgaag ttattcatcc caggatatcta atacatgtat ccaaagtaaa 28800
aatccaagga atctgaacac ttcatctgc aaagctagga ataggtttga cattttcact 28860
ccaagaaaaa gttttttttt gaaaatagaa tagttgggat gagaggtttc tttaaaagaa 28920
gactaactga tcacattact atgattctca aagaagaaac caaaacttca tataatacta 28980
taaagtaaat ataaaatagt tccttctata gtatatattct ataagtctac agtttaaaca 29040
gatcactctt atataatact attttgattt tgatgtagaa ttgcacaaat tgatatttct 29100
cctatgatct gcagggtata gcttaaagta acaaaaacag tcaaccacct ccatttaaca 29160
cacagtaaca ctatgggact agttttatta ctccatttt acaaatgagg aaactaaagc 29220
ttaaagatgt gtaatacacc gcccaaggtc acacagctgg taaagggtga tttcatccca 29280
gacagttaca gtcattgcca tgggcacagc tcctaactta gtaactccat gtaactggta 29340
ctcagtgtag ctgaattgaa aggagagtaa ggaagcaggt tttacaggtc tacttgact 29400
attcagagcc cgagtgtgaa tcctgtctgt gctgcttga gaagttactt aacctatgca 29460
aggttcattt tgtaaattt ggaaatggag tgataatacg tacttcacca gaggatttaa 29520
tgagacctta tacgatcctt agttcagtag ctgactatgt cttcataaat gctttttcat 29580
ccaatctgac aatctccagc ttgtaattgg ggcatttga acatttaata tgattattgg 29640
catggtaggt taaagctgct atcttctgtt tttctatttg ttctttttgt tttctcctta 29700
cttttgatt tttttattct actatgtctt ttctattgtc ttattaacta tactctttga 29760
tttatttttag tggttgtttt aggggttatac ctctttctaa tttaccagtt tataaccagt 29820
ttatatacta cttgacatat agcttaagaa acttactggt gttgtctttt tgctgttatg 29880
gtcttaacgt ttttatttct acaaacatta taaactccac actttattgt tttttaattt 29940
tacttataca gtcaattatc ttttaaagat atttaaatat aaacattcaa aacaccccaa 30000
t                                                                 30001

```

```

<210> SEQ ID NO 2
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 2

```

```

tgcccccgcc cccggcccca a 21

```

```

<210> SEQ ID NO 3
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

```

```

<400> SEQUENCE: 3

```

```

tcggccccgg ccccgcccca a 21

```

```

<210> SEQ ID NO 4
<211> LENGTH: 21
<212> TYPE: DNA

```

-continued

<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 4

tccggccccg gccccggcca a 21

<210> SEQ ID NO 5
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 5

tccccggcccc ggccccggca a 21

<210> SEQ ID NO 6
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 6

tccccggcccc cggccccgga a 21

<210> SEQ ID NO 7
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 7

tgccccggcc cggccccga a 21

<210> SEQ ID NO 8
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 8

tggccccgac cccggcccca a 21

<210> SEQ ID NO 9
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 9

tcggccccag cccggcccca a 21

<210> SEQ ID NO 10
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 10

tccggcccag gccccggcca a 21

<210> SEQ ID NO 11

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 11

tccccggccac ggccccggca a 21

<210> SEQ ID NO 12

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 12

tccccggcac cggccccgga a 21

<210> SEQ ID NO 13

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 13

tgccccggac cggccccga a 21

<210> SEQ ID NO 14

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 14

tggccccgac cccagcccca a 21

<210> SEQ ID NO 15

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 15

tcggccccag cccaggccca a 21

<210> SEQ ID NO 16

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 16

tccggcccag gccacggcca a 21

-continued

<210> SEQ ID NO 17
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 17

tccccggccac ggcaccggca a 21

<210> SEQ ID NO 18
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 18

tccccggccac cggacccgga a 21

<210> SEQ ID NO 19
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 19

tgccccggac cgcacccga a 21

<210> SEQ ID NO 20
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 20

tgccccgaa accggccca a 21

<210> SEQ ID NO 21
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 21

tcggcccaa acccgccca a 21

<210> SEQ ID NO 22
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 22

tccggcccaa acccgccca a 21

<210> SEQ ID NO 23
<211> LENGTH: 21
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 23

tccccggccaa agccccggca a 21

<210> SEQ ID NO 24
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 24

tccccggcaa aggccccgga a 21

<210> SEQ ID NO 25
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 25

tgccccggaa acggccccga a 21

<210> SEQ ID NO 26
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 26

tggggccggg gccggggcca a 21

<210> SEQ ID NO 27
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 27

tcggggccgg gccgggggca a 21

<210> SEQ ID NO 28
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 28

tccggggccg gggccgggga a 21

<210> SEQ ID NO 29
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 29

tgccggggcc ggggccggga a 21

<210> SEQ ID NO 30

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 30

tggccggggc cggggccggga a 21

<210> SEQ ID NO 31

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 31

tggggccgggg ccggggccga a 21

<210> SEQ ID NO 32

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 32

tggggccgag gccggggcca a 21

<210> SEQ ID NO 33

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 33

tcggggccag ggccggggca a 21

<210> SEQ ID NO 34

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 34

tccggggcag gggccgggga a 21

<210> SEQ ID NO 35

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 35

tgccggggac ggggccggga a 21

-continued

<210> SEQ ID NO 36
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 36

tggcggggac cggggcgga a 21

<210> SEQ ID NO 37
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 37

tgggcccggag cggggcgga a 21

<210> SEQ ID NO 38
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 38

tggggcccag gccaggcca a 21

<210> SEQ ID NO 39
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 39

tcggggccag ggcagggga a 21

<210> SEQ ID NO 40
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 40

tccggggcag gggacggga a 21

<210> SEQ ID NO 41
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 41

tgccggggac gggaccggga a 21

<210> SEQ ID NO 42
<211> LENGTH: 21
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 42

tggccgggac cggagccgga a 21

<210> SEQ ID NO 43
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 43

tgggcccggag ccgaggccga a 21

<210> SEQ ID NO 44
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 44

tggggccgaa accggggcca a 21

<210> SEQ ID NO 45
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 45

tcggggccaa agccggggga a 21

<210> SEQ ID NO 46
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 46

tccggggcaa aggccgggga a 21

<210> SEQ ID NO 47
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 47

tgccggggaa agggccggga a 21

<210> SEQ ID NO 48
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 48

tggccgggaa aggggccgga a 21

<210> SEQ ID NO 49

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 49

tggggccgga acggggccga a 21

<210> SEQ ID NO 50

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(21)

<223> OTHER INFORMATION: bases at these positions are RNA

<400> SEQUENCE: 50

tcugcugcaa augcugcuga a 21

<210> SEQ ID NO 51

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1)..(21)

<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 51

nnnnnnnnnn nnnnnnnnnn n 21

<210> SEQ ID NO 52

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (2)..(21)

<223> OTHER INFORMATION: bases at these positions are RNA

<400> SEQUENCE: 52

taacuucagg gucagcuuga a 21

<210> SEQ ID NO 53

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1)..(19)

<223> OTHER INFORMATION: bases at these positions are RNA

-continued

<400> SEQUENCE: 53

cggccccgaa accggccct t

21

<210> SEQ ID NO 54

<211> LENGTH: 21

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (1)..(19)

<223> OTHER INFORMATION: bases at these positions are RNA

<400> SEQUENCE: 54

gcuaauaccag cgucgucat t

21

<210> SEQ ID NO 55

<211> LENGTH: 22

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 55

agaaggcaca gagagaatgg aa

22

<210> SEQ ID NO 56

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 56

tcacatcatcat tgagtactgt atcagc

26

<210> SEQ ID NO 57

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 57

acgcctgcac aatttcagcc caa

23

<210> SEQ ID NO 58

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 58

caagtctgtg tcacatcogga gctg

24

<210> SEQ ID NO 59

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

-continued

<400> SEQUENCE: 59

gtcatcaatg gaaatcccat cac

23

<210> SEQ ID NO 60

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 60

ttctccatgg tgggaagac

20

1. A compound comprising a modified single-stranded RNA and a terminal group at the 5'-end of the modified single-stranded, wherein

the modified single-stranded consists of 13 to 30 linked nucleosides and has a nucleobase sequence comprising a complementary region having at least 7 contiguous nucleobases complementary to an equal-length portion within a target region of a target nucleic acid, wherein the target nucleic acid is a C9orf72 transcript; and wherein the terminal group comprises a phosphorus moiety.

2. The compound of claim 1, wherein the target region of the C9orf72 transcript comprises a hexanucleotide repeat.

3. The compound of claim 1, wherein the target region of the C9orf72 transcript is within a hexanucleotide repeat region.

4. The compound of claim 1, wherein the complementary region comprises at least 10 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

5. The compound of claim 1, wherein the complementary region comprises at least 12 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

6. The compound of claim 1, wherein the complementary region comprises at least 14 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.


7. The compound of claim 1, wherein the complementary region comprises at least 16 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

8. The compound of claim 1, wherein the complementary region comprises at least 18 contiguous nucleobases complementary to an equal-length portion within the target region of the C9orf72 transcript.

9. The compound of claim 1, wherein the C9orf72 transcript is a C9orf72 sense transcript.

10. The compound of claim 1, wherein the C9orf72 transcript is a C9orf72 antisense transcript.

11. The compound of claim 1, wherein the 5'-terminal nucleoside and terminal group of the compound has Formula I:




I

wherein:

T₁ is a phosphorus moiety;

A has a formula selected from among:



Q₁ and Q₂ are each independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, and N(R₃)(R₄);

Q₃ is selected from among: O, S, N(R₅), and C(R₆)(R₇); each R₃, R₄, R₅, R₆ and R₇ is independently selected from among: H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, and C₁-C₆ alkoxy;

M₃ is selected from among: O, S, NR₁₄, C(R₁₅)(R₁₆), C(R₁₅)(R₁₆)C(R₁₇)(R₁₈), C(R₁₅)=C(R₁₇), OC(R₁₅)(R₁₆), and OC(R₁₅)(Bx₂);

R₁₄ is selected from among: H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

R₁₅, R₁₆, R₁₇ and R₁₈ are each independently selected from among: H, halogen, C₁-C₆ alkyl, substituted

C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

if Bx₂ is present, then Bx₂ is a nucleobase and Bx₁ is selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

if Bx₂ is not present, then Bx₁ is a nucleobase;

either each of J₄, J₅, J₆ and J₇ is independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

or J₄ forms a bridge with one of J₅ or J₇ wherein the bridge comprises from 1 to 3 linked biradical groups selected from O, S, NR₁₉, C(R₂₀)(R₂₁), C(R₂₀)=C(R₂₁), C[=C(R₂₀)(R₂₁)] and C(=O) and the other two of J₅, J₆ and J₇ are independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, and substituted C₂-C₆ alkynyl;

each R₁₉, R₂₀ and R₂₁ is independently selected from among: H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

one of G₁ and G₂ is selected from among: H, OH, halogen and O—[C(R₈)(R₉)]_n—[(C=O)_m—X₁]_j—Z; and the other of G₁ and G₂ is: O-T₂;

T₂ is an internucleoside linking group linking the 5'-terminal nucleoside of Formula I to the remainder of the single-stranded;

each R₈ and R₉ is independently selected from among: H, halogen, C₁-C₆ alkyl, and substituted C₁-C₆ alkyl; X₁ is O, S or N(E₁);

Z is selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl, and N(E₂)(E₃);

E₁, E₂ and E₃ are each independently selected from among: H, C₁-C₆ alkyl, and substituted C₁-C₆ alkyl; n is from 1 to 6;

m is 0 or 1;

j is 0 or 1;

provided that, if j is 1, then Z is other than halogen or N(E₂)(E₃);

each substituted group comprises one or more optionally protected substituent groups independently selected from among: a halogen, OJ₁, N(J₁)(J₂), =NJ₁, SJ₁, N₃, CN, OC(=X₂)J₁, OC(=X₂)N(J₁)(J₂), and C(=X₂)N(J₁)(J₂);

X₂ is O, S or NJ₃; and

each J₁, J₂ and J₃ is independently selected from among: H and C₁-C₆ alkyl.


12. The compound of claim 11, wherein M₃ is selected from among: O, CH=CH, OCH₂, and OC(H)(Bx₂).

13. The compound of claim 5, wherein M₃ is O.

14. The compound of claim 11, wherein each of J₄, J₅, J₆ and J₇ is H.

15. The compound of claim 11, wherein J₄ forms a bridge with either J₅ or J₇.

16. The compound of claim 11, wherein A has the formula:



wherein:


Q₁ and Q₂ are each independently selected from among: H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, and substituted C₁-C₆ alkoxy.

17. The compound of claim 16, wherein each of Q₁ and Q₂ is H.

18. The compound of claim 16, wherein Q₁ and Q₂ are each independently selected from among: H and a halogen.

19. The compound of claim 16, wherein one of Q₁ and Q₂ is H and the other of Q₁ and Q₂ is F, CH₃ or OCH₃.

20. The compound of claim 11, wherein T₁ has the formula:



wherein:

R_a and R_c are each independently selected from among: hydroxyl, protected hydroxyl, thiol, protected thiol, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, amino, protected amino or substituted amino; and

R_b is O or S.

21. The compound of claim 20, wherein R_b is O and R_a and R_c are each, independently selected from among: OH, OCH₃, OCH₂CH₃, OCH(CH₃)₂.


22. The compound of claim 11, wherein one of G₁ and G₂ is selected from among: a halogen, OCH₃, OCH₂F, OCHF₂, OCF₃, OCH₂CH₃, O(CH₂)₂F, OCH₂CHF₂, OCH₂CF₃, OCH₂—CH=CH₂, O(CH₂)₂—OCH₃, O(CH₂)₂—SCH₃, O(CH₂)₂—OCF₃, O(CH₂)₃—N(R₁₀)(R₁₁), O(CH₂)₂—ON(R₁₀)(R₁₁), O(CH₂)₂—O(CH₂)₂—N(R₁₀)(R₁₁), OCH₂C(=O)—N(R₁₀)(R₁₁), OCH₂C(=O)—N(R₁₂)(CH₂)₂—N(R₁₀)(R₁₁), and O(CH₂)₂—N(R₁₂)—C(=NR₁₃)[N(R₁₀)(R₁₁)] wherein R₁₀, R₁₁, R₁₂ and R₁₃ are each, independently, H or C₁-C₆ alkyl.

23. The compound of claim 11, wherein one of G₁ and G₂ is selected from among: a halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH=CH₂, O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(=O)—N(H)CH₃, OCH₂C(=O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(=NH)NH₂.

24. The compound of claim 11, wherein one of G₁ and G₂ is selected from among: F, OCH₃, and O(CH₂)₂—OCH₃.


25. The compound of claim 24, wherein one of G₁ and G₂ is O(CH₂)₂—OCH₃.

26. The compound of claim **11**, wherein the 5'-terminal nucleoside and terminal group of the compound has Formula III:



III


27. The compound of claim **26**, wherein A has the formula:



wherein Q_1 and Q_2 are each independently selected from among: H, a halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_1 - C_6 alkoxy, and substituted C_1 - C_6 alkoxy.

28. The compound of claim **27**, wherein Q_1 and Q_2 are each independently selected from among: H, F, CH_3 , and OCH_3 .

29. The compound of claim **11**, wherein the 5'-terminal nucleoside and the terminal group has Formula V:



V

wherein:

Bx is selected from among: uracil, thymine, cytosine, 5-methyl cytosine, adenine, and guanine;

one of G_1 and G_2 is selected from among: a halogen, OCH_3 , OCF_3 , OCH_2CH_3 , OCH_2CF_3 , $OCH_2CH=CH_2$, $O(CH_2)_2OCH_3$, $O(CH_2)_2O(CH_2)_2N(CH_3)_2$, $OCH_2C(=O)N(H)CH_3$, $OCH_2C(=O)N(H)(CH_2)_2N(CH_3)_2$ and $OCH_2N(H)C(=NH)NH_2$;

and the other of G_1 and G_2 is $O-T_2$, wherein T_2 is a phosphorothioate internucleoside linking group linking the compound of Formula V to the remainder of the single-stranded.

30. The compound of claim **1**, wherein the modified single-stranded comprises at least two modified sugar moieties.

31. The compound of claim **30**, wherein the modified single-stranded is fully modified.

32. The compound of claim **30**, wherein each modified sugar moiety is independently selected from among: 2'-F, 2'-MOE, 2'-OMe, LNA, F-HNA, and cEt.

33-92. (canceled)

* * * * *